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ABSTRACT OF DISSERTATION
DISRUPTIONS IN THE REGULATION OF EXTRACELLULAR GLUTATMATE AFTER
DIFFUSE BRAIN INJURY
By
Jason Michael Hinzman
Glutamate, the predominant excitatory neurotransmitter in the central nervous
system, is involved in almost all aspects of neurological function including cognition,
motor function, memory, learning, decision making, and neuronal plasticity. For normal
neurological function, glutamate signaling must be properly regulated. Disrupted
glutamate regulation plays a pivotal role in the acute pathophysiology of traumatic brain
injury (TBI), disrupting neuronal signaling, initiating secondary injury cascades, and
producing excitotoxicity. Increases in extracellular glutamate have been correlated with
unfavorable outcomes in TBI survivors, emphasizing the importance of glutamate
regulation.
The aim of this thesis was to examine disruptions in the regulation of extracellular
glutamate after experimental TBI. In these studies, we used glutamate-sensitive
microelectrode arrays (MEAs) to examine the regulation of extracellular glutamate two
days after diffuse brain injury. First, we examined which brain regions were vulnerable to
post-traumatic increases in extracellular glutamate. We detected significant increases in
extracellular glutamate in the dentate gyrus and striatum, which correlated to the severity
of brain injury. Second, we examined the regulation of extracellular glutamate by
neurons and glia to determine the mechanisms responsible for post-traumatic increases
in extracellular glutamate. In the striatum of brain-injured rats, we detected significant
disruptions in release of glutamate by neurons and significant decreases in the removal
of glutamate from the extracellular space by glia. Third, we examined if a novel
therapeutic strategy, a viral-vector mediated gene delivery approach, could improve the
regulation of extracellular glutamate. Infusion of an adeno-associated virus expressing a
glutamate transporter into the rat striatum produced significant improvements in
glutamate clearance, identifying a novel strategy to reduce excitotoxicity. Lastly, we
examined the translational potential of MEAs as novel neuromonitoring device for clinical
TBI research. Overall, these studies have demonstrated the translational potential of
MEAs to aid in the diagnosis and treatment of TBI survivors.
KEYWORDS: midline fluid percussion injury, amperometry, excitatory amino acid
transporters
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Chapter One: Introduction
Traumatic Brain Injury
Recent estimates indicate that traumatic brain injury (TBI) produces 50,000
deaths, 235,000 hospitalizations, and 1.1 million visits to the emergency department
annually in the United States. Nationally, the top three causes of TBI are falls (28%),
motor vehicle crashes (20%), and being struck by an object or person (19%) (Corrigan,
et al. 2010). TBI is a heterogeneous disorder producing a wide range of symptoms
based on the severity of the injury. The Glasgow coma scale (GCS) was developed to
reliably classify the severity of a TBI based on the patient’s eye, verbal, and motor
responses with a total GCS score of (≥13) for mild injury, (9-12) for moderate injury, and
(≤8) for severe injury (Table 1.1) (Narayan, et al. 2002). TBI results in various anatomical
changes within the central nervous system including hemorrhage (subarachnoid and
intraventricular), hematoma (epidural, subdural, and parenchymal), diffuse axonal injury,
and contusion (Saatman, et al. 2008). Presently, there are no approved therapeutics for
the treatment of TBI, instead current medical care focuses on maintaining proper
physiological parameters such as intracranial pressure and blood pressure (Wang, et al.
2006).
Traumatic brain injury contains two distinct pathophysiological processes,
primary injury and secondary injury (McIntosh, et al. 1996). Primary injury is the result of
mechanical forces producing tissue deformation at the time of injury that damages blood
vessels, shears axons, and produces cellular damage (Reilly and Bullock 1997, Gaetz
2004). Secondary injury, a consequence of the primary tissue damage, propagates
damage through complex biochemical and cellular pathways (McIntosh, et al. 1996,
Reilly and Bullock 1997). Secondary injury, which occurs in the hours to days after
injury, is the target of therapies to reduce or limit damage to improving outcomes in TBI
survivors (Bullock, et al. 1995, Myseros and Bullock 1995, Reilly and Bullock 1997).
Recent evidence suggests that TBI is more than a single event; instead, it involves a
complex disease process with the long term consequences including an increased risk
for epilepsy, sleep disorders, neurodegenerative diseases, neuroendocrine disorders,
psychiatric disorders, and reduced life expectancy (Masel and DeWitt 2010).
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Glutamate’s Role as a Neurotransmitter in the Central Nervous System
Glutamate, the predominant excitatory neurotransmitter in the central nervous
system, is involved in almost all aspects of neurological function including cognition,
motor function, memory, learning, decision making, and neuronal plasticity (McEntee
and Crook 1993). In nerve terminals, glutamate is synthesized from multiple sources for
neurotransmission. Glutamate can be synthesized from glucose via the Krebs cycle,
transamination of α-oxoglutarate by alanine transaminase, and conversion of glutamine
by glutaminase (Cooper, et al. 2003). High concentrations of glutamate are packaged
into synaptic vesicles by vesicular glutamate transporters (vGluTs) using a protondependent electrochemical gradient across the vesicle membrane to transport glutamate
against the concentration gradient (Takamori 2006). Glutamate is released into the
extracellular space by two mechanisms. First, classical release of glutamate by neurons
involves the opening of voltage-gated calcium channels after neuronal depolarization,
permitting calcium influx into the nerve terminal. Calcium influx induces membrane
fusion of the vesicles and exocytosis of glutamate into the extracellular space (Danbolt
2001, Cooper, et al. 2003). Second, glutamate is released into the extracellular space
via carrier mediated exchange with other amino acids (Jabaudon, et al. 1999, Jensen, et
al. 2000). Once in the extracellular space glutamate binds to ionotropic and metabotropic
glutamate receptors for signal propagation (Fig 1.1).
There are three major types of ionotropic glutamate receptors (iGluRs), named
after the agonist that would selectively activate them: N-methyl-D-aspartate (NMDA), αamino-3-hydroxy-5-methyl-4-isoazolepropionic

acid

(AMPA),

and

2-carboxy-3-

carboxymethyl-4-isopropenylpyrrolidine (Kainate, KA) (Table 1.2). The iGluRs are
ligand-gated ion channels responsible for modulating post-synaptic excitability and
plasticity (Kew and Kemp 2005). AMPA and KA receptors are involved in fast excitatory
neurotransmission; glutamate binding produces a conformational change in both
receptors permitting sodium influx into the post-synaptic neuron (Greene and
Greenamyre 1996). Compared to AMPA and KA receptors, the NMDA receptor requires
multiple steps for activation. First, the NMDA receptor requires binding of two ligands,
glutamate and glycine. Second, because the NMDA receptor is a voltage-sensitive ion
channel, it requires depolarization to release the magnesium block and permit calcium
influx. Glutamate binding to AMPA and KA receptors permits sodium influx into the cell,
responsible for depolarizing the post-synaptic neuron and removing the magnesium
block. Binding of glutamate and glycine, while the post-synaptic neuron is in a
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depolarized state, will then open the ion channel of the NMDA receptor permitting
calcium influx (Gardoni and Di Luca 2006).
There are a total of eight metabotropic glutamate receptors (mGluRs), organized
into three groups (Table 1.3). mGluRs are G-protein coupled receptors using second
messenger responses for signal transduction. mGluRs regulate the release of glutamate,
post-synaptic excitability, packaging of glutamate into vesicles, and uptake of glutamate
from the extracellular space (Schoepp 2001, Swanson, et al. 2005). Since mGluRs use
secondary messenger systems for signal propagation, signaling is generally slower
compared to activation of iGluRs. mGluRs contain seven alpha-helical transmembrane
domains with a ligand binding site located on the extracellular N-terminus (Kew and
Kemp 2005). Group I (mGluR1 and mGluR5) are excitatory localized on the post-synaptic
terminals of glutamatergic neurons. Group II (mGluR2 and mGluR3) receptors are
inhibitory with mGluR2 localized primarily on pre-synaptic glutamatergic terminals, while
mGluR3 is expressed on glial as well as pre- and post-synaptic glutamatergic neurons.
Group III (mGluR4, mGluR6, mGlu7 and mGluR8) are inhibitory with mGluR4 and mGluR7
receptors localized pre- and post-synaptically (Schoepp 2001) (Refer to Table 1.2 for
localization and function of mGluRs).
For normal neurological function, extracellular concentrations of glutamate must
be properly regulated. Appropriate activation of glutamate receptors requires the
extracellular concentration of glutamate to remain low, producing a high signal-to-noise
ratio during synaptic release of glutamate. Since there are no extracellular enzymes to
degrade glutamate, low concentrations of extracellular glutamate are maintained by the
uptake of glutamate via five high affinity sodium-dependent excitatory amino acid
transporters (EAATs) (EAAT1, GLAST) (EAAT2, GLT-1), (EAAT3, EAAC), EAAT4, and
EAAT5 (Danbolt 2001)(Table 1.4). Glutamate uptake is an electrogenic process using
the negative membrane potential maintained by the sodium/potassium adenosine
triphosphatase to transport glutamate. Uptake of glutamate by the EAATs requires both
sodium and potassium ions; sodium for glutamate binding and potassium for glutamate
transport. During glutamate transport, one molecule of glutamate, three sodium ions,
and one hydrogen ion are transported into the cell, while one potassium ion is
transported out of the cell (Danbolt 2001). A majority (~90%) of glutamate uptake is
performed by two glial transporters in the rat forebrain, GLAST and GLT-1 (Rothstein, et
al. 1996, Tanaka, et al. 1997, Danbolt 2001).
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Glutamate’s Role in the Pathophysiology of TBI
While glutamate normally functions as an excitatory neurotransmitter, increases
in extracellular glutamate can lead to excessive stimulation of glutamate receptors
producing cell death by a mechanism termed “excitotoxicity” (Lucas and Newhouse
1957, Olney and de Gubareff 1978). Excitotoxicity was described as a phenomenon
whereby

the

excitatory

action

of

glutamate

becomes

neuropathological process that rapidly kills neurons (Olney and

transformed

into

a

de Gubareff 1978).

Excitotoxicity involves the activation of complex biochemical and cellular pathways that
produce prolonged depolarization of neurons, increased concentrations of intracellular
calcium, and activation of enzymatic and nuclear mechanisms of cell death (Doble
1999). Increases in extracellular glutamate have been shown to play a pivotal role in the
initiation and propagation of secondary brain injury (Fig 1.2). The mechanical forces of
the primary brain injury compromise the blood-brain barrier and cellular membranes
releasing glutamate into the extracellular space (Schmidt and Grady 1993, Bullock, et
al. 1998, Farkas, et al. 2006). Also, redistribution of ions from the primary injury creates
a massive depolarization leading to neuronal release of glutamate (Katayama, et al.
1990). The massive increase in extracellular glutamate at the initial time of injury has
been well characterized in experimental models of traumatic brain injury (Faden, et al.
1989, Katayama, et al. 1990, Nilsson, et al. 1990, Palmer, et al. 1993, Globus, et al.
1995, Katoh, et al. 1997, Stoffel, et al. 1997, Matsushita, et al. 2000, Rose, et al. 2002,
Stoffel, et al. 2002).
The initial surge of glutamate at the time of injury leads to excessive activation of
iGluRs and mGluRs, and increases glutamate uptake by the EAATs to restore the
extracellular glutamate concentration. The above processes lead to increase ionic flux
into the cell. First, increases in extracellular glutamate activate AMPA and KA receptors
permitting sodium influx into the cell and depolarizing the cell (Greene and Greenamyre
1996). Second, depolarization opens voltage-sensitive calcium channels and removes
the magnesium block from the NMDA receptor, which allows further calcium influx into
the cell (Gardoni and Di Luca 2006). Third, activation of Group I mGluRs by glutamate
leads to the opening of voltage-gated calcium channel permitting calcium influx (Mao
and Wang 2002). Lastly, uptake of glutamate by the EAATs results in sodium influx into
the cell (Danbolt 2001). To maintain ionic equilibrium in the cell, chloride ions passively
diffuse into the cell along with water creating osmotic swelling of the cell. Cytoxic edema
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directly contributes to raising the intracranial pressure (ICP), one of the most common
sequelae of secondary brain injury (Marmarou 2004).
To restore ionic equilibrium in the cell, the sodium-potassium pump actively
transports sodium out of the cell. Since the sodium-potassium pump is driven by the
hydrolysis of adenosinetriphospate (ATP), reestablishing the ionic equilibrium can
deplete ATP levels in the cell (Tavalin, et al. 1997). After TBI, there is an increase in
glucose transport to facilitate glycolysis and ATP generation (Kawamata, et al. 1995).
Restoring

the

ATP

concentration

through

oxidative

phophsorylation

leads

to

mitochondrial dysfunction as the mitochondria attempt to maintain the energy supply
(Sullivan, et al. 2005). Mitochondrial dysfunction leads to the production of reactive
oxygen species (ROS) and oxidative damage that includes protein nitration and lipid
peroxidation (Braughler and

Hall 1992, Hall, et al. 1994, Singh, et al. 2006).

Mitochondrial dysfunction and oxidative damage are well established sequelae of
secondary brain injury (Braughler and Hall 1992, McIntosh, et al. 1996, Sullivan, et al.
2005). Mitochondrial dysfunction in a state of increased glycolysis leads to anaerobic
glycolysis and the production of lactate as an alternate energy supply. TBI produces
significantly higher levels of lactate in the brain, with a correlation between lactate levels
and reduced outcomes in TBI survivors (Reilly and Bullock 1997, Makoroff, et al. 2005).
A pivotal process in the secondary injury cascade is calcium influx into the cell,
the ability of the cell to survive depends on the buffering capacity of the mitochondria
and endoplasmic reticulum to sequester cytosolic calcium (Doble 1999). If the cell is
unable to buffer the calcium influx, calcium overload can trigger many irreversible
neurotoxic cascades, including the uncoupling mitochondrial electron transfer from ATP
synthesis, the activation and overstimulation of enzymes such as calpains and other
proteases, protein kinases, nitric oxide synthase, calcineurins, and endonucleases
(Nasr, et al. 2003, Arundine and Tymianski 2004, Lifshitz, et al. 2004, Sullivan, et al.
2005). The above processes lead to cellular damage and dysfunction, responsible for
the activation of apoptotic/necrotic mechanisms of cell death (Nicholls and Budd 2000,
Sattler and Tymianski 2000). Reducing or preventing increases in cytosolic calcium and
the activation of neurotoxic cascades has been the therapeutic target of multiple
compounds to provide neuroprotection and improved outcomes after TBI (Okonkwo, et
al. 1999, Sullivan, et al. 2004, Geddes and Saatman 2010, Saatman, et al. 2010).
Increases in extracellular glutamate not only initiate secondary injury cascades,
but the downstream consequences of secondary injury lead to further increases in

5

extracellular glutamate that amplify and propagate damage. First, increased ionic flux
can depolarize neurons and enhance vesicular glutamate release. Second, structural
damage to the cell can lead to a loss of membrane fidelity allowing glutamate to leak into
the extracellular space (Yi and Hazell 2006). Third, release of inflammatory cytokines
can activate microglia, which release glutamate into the extracellular space via the
glutamate/cystine exchanger (Barger, et al. 2007). Fourth, disruptions in the ionic
equilibrium and oxidative damage to the EAATs can inhibit the ability of the EAATs to
uptake glutamate from the extracellular space (Trotti, et al. 1998). Overall, increases in
the release of glutamate and decreases in the ability to uptake glutamate can increase
the extracellular concentrations of glutamate diffusing to nearby neurons amplifying and
propagating secondary damage.
Clinically, a multitude of studies have detected significant increases in
extracellular glutamate levels in the days following injury with some reports correlating
increases in extracellular glutamate with unfavorable outcomes (Persson and Hillered
1992, Bullock, et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 1998,
Yamamoto, et al. 1999, Reinert, et al. 2000, Hutchinson, et al. 2002, Hlatky, et al. 2004,
Chamoun, et al. 2010, Lakshmanan, et al. 2010, Timofeev, et al. 2011a). Based on the
large body of clinical evidence supporting a role for increased glutamate release and
excessive glutamate receptor activation in pathophysiology of TBI, many compounds
have been developed to modulate aspects of glutamate signaling. The NMDA receptor
has been the primary therapeutic target to reduce excitotoxicity (Muir 2006).
Unfortunately, NMDA antagonists have failed to reach their primary endpoints in
randomized controlled trials in head-injured patients (Willis, et al. 2004). One of the
major problems encountered with the NMDA antagonists trials were adverse effects that
include hallucinations, catatonia, ataxia, nightmares, and memory deficits (Blanke and
VanDongen 2009).
Unlike the clinical studies, multiple animals studies report increases in
extracellular glutamate at the time of the injury, which returns to baseline concentrations
within the first hour after injury (Faden, et al. 1989, Katayama, et al. 1990, Nilsson, et al.
1990, Palmer, et al. 1993, Globus, et al. 1995, Katoh, et al. 1997, Stoffel, et al. 1997,
Matsushita, et al. 2000, Rose, et al. 2002, Stoffel, et al. 2002). Since experimental TBI
has failed to model glutamate dysregulation seen in the clinic, the role of glutamate
excitotoxicity in the acute pathophysiology of TBI has been challenged and remains
unclear (Carbonell and Grady 1999, Obrenovitch 1999). All of the prior studies have
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used microdialysis, a common method for neurochemical sampling in vivo. However,
microdialysis suffers from methodological limitations that restrict the ability of
microdialysis to sample glutamate near the synapse, due to poor spatial and temporal
resolution and extensive damage from implantation of the probe (Obrenovitch, et al.
2000, Borland, et al. 2005, Diamond 2005, Hillered, et al. 2005, Jaquins-Gerstl and
Michael 2009).
In this thesis, we will re-examine glutamate dysregulation in the acute
pathophysiology of experimental brain injury using a novel technique, enzyme-based
microelectrode arrays (MEAs). MEAs have improved upon some methodological
limitations inherent to microdialysis allowing measures of extracellular glutamate closer
to the synapses (Burmeister and Gerhardt 2001, Burmeister, et al. 2002, Day, et al.
2006, Hascup, et al. 2010). We will use MEAs to examine disruptions in the regulation of
extracellular glutamate in brain regions that may be responsible for post-traumatic
deficits in behavioral, cognitive, and motor function. The overall goal of this thesis is to
examine the regulation of extracellular glutamate after a TBI, identify novel therapeutic
targets to improve the regulation of extracellular glutamate, and examine possible
therapeutic approaches to improve regulation of extracellular glutamate.

Copyright © Jason Michael Hinzman 2012
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Chapter One: Figures

Figure 1.1 Schematic of a glutamate synapse
Several aspects of glutamate neurotransmission are depicted in the diagram of a
glutamate synapse. Glutamate is packaged into vesicles by vesicular glutamate
transporters (vGluT). Glutamate is released in the extracellular space in a Ca2+dependent mechanism upon membrane depolarization. Glutamate can also be released
from non-neuronal sources, such as the cystine/glutamate exchanger. Once in the
extracellular space, glutamate propagates downstream signaling by binding to both
metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors
(iGluRs). Glutamate is removed from the extracellular space by sodium-dependent, high
affinity excitatory amino acid transporters (EAATs), regulating the extracellular glutamate
concentration and activation of glutamate receptors.
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Glutamate

Glutamate Receptor
Activation

Glutamate Uptake

Na+ Ca2+ Influx

Na +/K+ Activity

Cl- Influx

Activation of Proteases
and Lipases

ATP Depletion

Cellular Swelling

Protein, Enzyme,
and Membrane Damage
Cellular Dysfunction/
Apoptosis/Necrosis

Mitochondrial Stress

Oxidative Damage

ICP

Free Radicals and
Reactive Oxygen Species

Figure 1.2 Schematic and diagram depicting glutamate’s role in the initiation,
propagation, and amplification of secondary brain injury
Schematic (A) and diagram (B) depicting glutamate’s role in the complex biochemical
and cellular pathways involved in secondary brain injury.
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Chapter One: Tables
Table 1.1 Glasgow Coma Scale (GCS)

Score

1

2

3

4

Eyes

Does not
open eyes

Opens eyes
to painful
stimuli

Opens eyes
to voice

Opens eyes
spontaneoulsy

Verbal

Does not
make sound

Incomprehen
sible sound

Sounds
inappropiate
words

Confused or
disorinted

Converses
normally

Motor

Does not
move

Extension to
painful stimuli

Abnormal
flexion to
painful stimuli

Flexion
withrdrawl to
painful stimuli

Localizes
painful
stimuli

Severity

GCS (Total Score)

Minor

≥ 13

Moderate

9-12

Severe

≥8

5

6

Obeys
commands

Table 1.2 Ionotropic Glutamate Receptors

NMDA

AMPA

Kainate

Receptor

NR1, NR2A, NR2B NR2C,

GluR1, GluR2,

GluR5, GluR6

Subunits

NR2D NR3A, NR3B

GluR3, GluR4

GluR7, KA-1 KA-2

Ca2+, Na+

Na+ (Ca2+)

Na+ (Ca2+)

Signal
Transduction
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Table 1.3 Metabotropic Glutamate Receptors

Localization

Function

Pre-synaptic

Enhances excitability

Post-synaptic

Synaptic plasticity, LTP/LTD

mGluR5

Post-synaptic and glia

Synaptic plasticity, LTD

mGluR2

Pre-synaptic

LTD

mGluR3

Pre/Post-synaptic and glia

Neurotropin release

mGluR4

Pre/Post-synaptic

Motor learning

mGluR6

Retina

Visual acuity

Pre/Post-synaptic

Autoreceptor

Pre-synaptic

Regulation of lateral perforant
path

mGluR1

Group III

Group II

Group I

Receptor

mGluR7

mGluR8
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Table 1.4 Excitatory Amino Acid Transporters (EAATs)
Human
Nomenclature
EAAT1

EAAT2

EAAT3

Rodent
Nomenclature
Glutamate aspartate
transporter (GLAST)
Rat glutamate
transporter (GLT-1)
Rabbit glutamate
transporter (EAAC)

Localization

Astrocytes

Astrocytes

Postsynaptic neurons

Cerebellar Purkinje neurons

EAAT4

(human)

EAAT 5

Retina (human)
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Preface to Chapter Two
The aim of the experiments in Chapter Two was to examine if an experimental
model of diffuse traumatic brain injury (TBI) produced post-traumatic disruptions in the
regulation of tonic glutamate and potassium-evoked glutamate release in brain regions
that may be responsible for post-traumatic deficits in behavioral, cognitive, and motor
function. Using glutamate-sensitive microelectrode arrays (MEAs), I detected discrete
regional changes in tonic glutamate and potassium-evoked glutamate release that were
dependent on the severity of injury. In the end, I demonstrated that glutamate-sensitive
MEAs were able to detect disruptions in the regulation of extracellular glutamate twodays after diffuse brain injury.

Chapter Two: Diffuse Brain Injury Elevates Tonic Glutamate Levels and
Potassium-Evoked Glutamate Release in Discrete Brain Regions
at Two Days Post-Injury: an Enzyme-Based Microelectrode Array Study

Abstract
Traumatic brain injury (TBI) survivors often suffer from a wide range of posttraumatic deficits including impairments in behavioral, cognitive, and motor function.
Regulation of glutamate signaling is vital for proper neuronal excitation in the central
nervous system. Without proper regulation, increases in extracellular glutamate can
contribute to the pathophysiology and neurological dysfunctions seen in TBI. In the
present studies, enzyme-based microelectrode arrays (MEAs) that selectively measure
extracellular glutamate at 2 Hz enabled the examination of tonic glutamate levels and
potassium chloride (KCl)-evoked glutamate release in the prefrontal cortex, dentate
gyrus, and striatum of adult male rats two days after mild or moderate midline fluid
percussion brain injury. Moderate brain injury significantly increased tonic extracellular
glutamate levels by 256% in the dentate gyrus and 178% in the dorsal striatum. In the
dorsal striatum, mild brain injury significantly increased tonic glutamate levels by 200%.
Tonic glutamate levels were significantly correlated with injury severity in the dentate
gyrus and striatum. The amplitudes of KCl-evoked glutamate release were increased
significantly only in the striatum after moderate injury, with a 249% increase seen in the
dorsal striatum. Thus, with MEAs, we measured discrete regional changes in both tonic
and KCl-evoked glutamate signaling, which were injury severity dependent. Future
studies may reveal the specific mechanisms responsible for glutamate dysregulation in
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the post-traumatic period, providing novel therapeutic targets to improve outcomes after
TBI.

Introduction
Approximately 1.5 million Americans suffer from a traumatic brain injury (TBI)
each year, with mild TBI accounting for as many as 75% of all the injuries (Centers for
Disease Control and Prevention, 2003). Survivors of TBI often suffer from a wide variety
of neurological deficits that impair quality of life (Baddeley 1992, Capruso and Levin
1992, McAllister 1992, Levine, et al. 2002). Glutamate signaling in the central nervous
system (CNS) plays a pivotal role in the acute pathophysiology of TBI. Primary
mechanical forces of the initial injury can compromise the blood-brain barrier and cellular
membranes allowing increased glutamate release into the extracellular space (Schmidt
and Grady 1993, Bullock, et al. 1998, Farkas, et al. 2006). The redistribution of ions
after injury can further depolarize neurons and augment the release of glutamate
(Katayama, et al. 1990). Excessive glutamate receptor activation can promote cellular
damage through secondary injury cascades by disrupting ionic homeostasis in the cell,
activating calcium-dependent proteases and phospholipases, uncoupling mitochondrial
ATP synthesis, promoting oxidative stress, producing reactive oxygen species, depleting
glutathione levels, and increasing the energy demand of the cell (Faden, et al. 1989,
Hall, et al. 1994, McIntosh, et al. 1996, Yi and Hazell 2006). Further, clinical reports
have reported increases in extracellular glutamate up to four days after injury that
correlated with increased intracranial pressure and unfavorable outcomes (Bullock, et al.
1995). These prior studies emphasize the consequences of CNS glutamate
dysregulation, and the need to examine changes in glutamate signaling in the posttraumatic period after TBI that may be responsible for aberrant neuronal signaling and
the contribution to neurological deficits.
Glutamate is released constantly into the extracellular space via stimulated and
spontaneous exocytosis of synaptic vesicles and by carrier mediated exchange with
other amino acids (Jabaudon, et al. 1999, Jensen, et al. 2000). Because there is no
enzyme in the extracellular fluid to degrade glutamate, the synaptic concentration of
glutamate is lowered by diffusion away from the synapse and through glutamate uptake.
Since diffusion of glutamate is limited by the extrasynaptic anatomy, glutamate uptake is
the primary mechanism to maintain the extracellular concentration of glutamate. In the
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central nervous system, almost all of the glutamate clearance is achieved by the sodiumdependent

excitatory

amino

acid

transporters

(EAATs)

GLAST

and

GLT-1,

predominantly located on glia (Danbolt 2001).
Previous studies have reported several fold increases in the extracellular
concentration of glutamate initiated by a TBI, which subside within two hours (Faden, et
al. 1989, Katayama, et al. 1990, Nilsson, et al. 1990, Matsushita, et al. 2000). These
studies employed microdialysis, a common method for neurochemical sampling in vivo.
However, microdialysis suffers from spatial and temporal limitations that restrict the
ability to sample dynamic fluctuations of glutamate near the synapse (Obrenovitch, et al.
2000, Hillered, et al. 2005). The large sampling area of the microdialysis membrane (1-4
mm length) and extensive damage from implantation of the microdialysis probe limit the
ability to detect neuronal release (Borland, et al. 2005, Jaquins-Gerstl and Michael
2009). Furthermore, the low temporal resolution of microdialysis (1-20 min) is
inadequate to sample the fast dynamics of glutamate release and clearance that occurs
on the order of milliseconds to seconds (Diamond 2005).
Interestingly, experimental TBI has yet to produce pathological extracellular
concentrations of glutamate, even immediately post-injury (Katayama, et al. 1990,
Matsushita, et al. 2000), which raises doubt about glutamate excitotoxicity after TBI
(Carbonell and Grady 1999, Obrenovitch 1999). In this study, we used midline fluid
percussion injury (FPI), a model of a diffuse closed head injury that affects both
hemispheres equally and shares pathological features of human head injuries (Dixon, et
al. 1987, McIntosh, et al. 1987), to examine changes in glutamate signaling two days
after mild or moderate diffuse brain injury. To study injury-induced alterations in
glutamate neurotransmission, we employed a novel technique, in vivo amperometry
coupled to enzyme-based microelectrode arrays (MEAs), with high temporal resolution
(2 Hz), low limit of detection (< 1 µM), and high spatial resolution to selectively measure
extracellular glutamate closer to synapses (Burmeister and Gerhardt 2001, Burmeister,
et al. 2002). The improved spatial and temporal resolution of the MEAs allowed us to
examine injury-induced alterations in tonic glutamate levels and potassium chloride
(KCl)-evoked glutamate release in the prefrontal cortex, dentate gyrus of the
hippocampus, and striatum; brain regions known to play a role in the behavioral,
cognitive, and motor deficits suffered by TBI survivors (Baddeley 1992, Capruso and
Levin 1992, McAllister 1992, Levine, et al. 2002).
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Methods
Animals
Male Sprague-Dawley rats (350-400g; Harlan Laboratories Inc., Indianapolis, IN)
were used for all experiments. The animals were housed in a 12 h light/dark cycle with
food and water ad libitum according to the Association for Assessment and Accreditation
of Laboratory Animal Care International. Animals were acclimated to their environment
for at least 1 week before any experiments. After surgery, animals were monitored daily
for post-operative care. Animal care was approved by the University of Kentucky
Institutional Animal Care and Use Committee.

Midline Fluid Percussion Injury
Animals were subjected to midline FPI as previously described (Lifshitz 2008).
Rats were anesthetized with isoflurane at 4% for five minutes and placed in a stereotaxic
frame in a sterile surgery hood with continuously delivered isoflurane at 2%. The head
was shaved and a 70% alcohol and betadine solution was applied. Eyes were treated
with artificial tears and body temperature was maintained with a delta-phase heating pad
(Braintree Scientific, Braintree, MA). A midline incision was made and fascia removed
from the skull. A 4.7 mm trephine was used for the craniotomy, centered on the sagittal
suture between bregma and lambda without disrupting the underlying dura or superior
sagittal sinus. Anchoring screws were secured into pilot holes remote from the
craniotomy. An injury hub was constructed from a Luer-Loc hub. The outer diameter of
the hub was beveled to match the craniotomy. The injury hub was fitted into the
craniotomy and cyanoacrylate gel was applied to seal the skull-hub interface. To secure
the injury hub to the anchoring screws, methyl-methacrylate (Hygenic Corp., Akron, OH)
was applied. The hub was filled with sterile saline and the wound sutured to prevent
tearing. The animals were allowed to recover for 30-60 minutes until ambulatory and
then re-anesthetized with 5% isoflurane for 5 minutes. The incision was opened and the
injury hub was inspected. The female Luer-Loc injury hub was connected to the male
Luer-Loc hub of the injury device (Custom Design and Fabrication, Virginia
Commonwealth University, Richmond, VA). Before reflexive responses returned, the
pendulum hammer was dropped onto the fluid-filled piston to induce either a mild or
moderate injury. Sham injured animals underwent the same procedure without induction
of injury. The fluid pressure pulse for mild injury was 1.1 ± 0.01 atm, and 2.0 ± 0.02 atm
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for moderate injury. The injury hub was removed and any bleeding controlled with
Gelfoam (Pharmacia, Kalamazoo, MI). The incision was closed with staples. Righting
reflex recovery times were recorded for the injury group, from the time of impact to the
time when animals’ spontaneously righted. Mild injured animals had righting reflex times
of 144 ±34 seconds (n=10), and moderate injured animals had times of 606 ±85 seconds
(n=11). Sham injured animals had righting reflex less than 15 seconds (n=10). No
animals died from complications caused by the injury.

Enzyme-Based Microelectrode Arrays
Ceramic-based MEAs, consisting of four platinum recording sites (15 x 333 µm)
arranged in dual pairs, were prepared and selected for in vivo recordings as previously
described (Burmeister, et al. 2002, Day, et al. 2006). Glutamate-oxidase (GluOX)
covered one pair of recording sites to allow for the enzymatic conversion of glutamate to
α-ketoglutarate and the generation of the reporter molecule H2O2. An inactive protein
matrix covered the other pair of recording sites (sentinel sites). The two different
coatings allowed the use of a self-referencing technique, in which the background
current of the sentinel sites can be subtracted from the current of the glutamate-oxidase
sites, thereby producing a more selective glutamate measure (Burmeister and Gerhardt
2001, Burmeister, et al. 2002). A size exclusion layer of 1,3-phenylenediamine (mPD)
restricted the passage of large molecules that can be oxidized, such as ascorbic acid
(AA) and dopamine (DA). Small molecules, such as H2O2, diffuse through the exclusion
layer, reaching the platinum recording sites (Fig 2.1A).
A 10 µL solution of 1% bovine serum albumin (BSA) (Sigma-Aldrich, St. Louis,
MO), 0.125% glutaraldehyde (Glut) (Sigma-Aldrich), and 1% glutamate-oxidase
(Seikagaku America, East Falmouth, MA) was prepared. Using a dissecting microscope,
a microsyringe was used to manually apply a small drop (~0.1µL) of the glutamateoxidase solution onto the bottom pair of platinum recording sites. Three enzyme coats
were applied onto the platinum recording sites with a one minute drying period between
each coat. The same procedure was used to coat the top pair of platinum recording sites
(sentinel sites) with a solution containing 1% BSA and 0.125% glutaraldehyde. After
coating, the MEAs were cured for at least 48 hours in a low humidity environment. The
coated MEAs were connected to the FAST-16 mkII system (Fast Analytical Sensor
Technology Mark II; Quanteon, L.L.C., Nicholasville, KY) and the tips of the MEAs were
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placed in a 5 mM mPD solution (Acros Organics, Morris Plains, NJ). Electroplating
software was used to apply a potential as a triangular wave with an offset of -0.5V, peak
to peak amplitude equal to 0.25V, at a frequency of 0.05 Hz, for a period of 20 minutes
to electroplate the mPD on all platinum recording sites. MEAs were cured for an
additional 24 hours in a low humidity environment before use.

MEA Calibration
Calibrations were conducted to test the capability of the MEAs to measure
glutamate and generate a standard curve for the conversion of current to glutamate
concentration. Constant potential amperometry was performed with the MEAs using a
FAST-16 mkII system. A potential of + 0.7 V versus a Ag/AgCl reference was applied to
oxidize the reporter molecule, H2O2, which is a 2-electron oxidation reaction that occurs
at the platinum recording sites of the MEA. The resulting current was amplified and
digitized by the FAST-16 mkII system. The platinum recording sites of the MEA were
placed in a continuously stirred 40 ml solution of 0.05 M phosphate buffered saline
(PBS) maintained at 37 ºC with a re-circulating water bath (Gaymar Industries Inc.,
Orchard Park, NY). The MEAs were exposed to final concentrations of 250 µM AA, 20,
40, 60 µM glutamate, 2 µM DA, and 8.8 µM H2O2 (Fig 2.1B). Parameters tested were
limit of detection (LOD), selectivity for glutamate over ascorbic acid, slope of the
electrode (sensitivity), and linearity of the glutamate response (R2). The average LOD
was 0.8 ±0.1 µM, selectivity was 167 ±19:1 (glutamate: ascorbic acid), and slope was
3.4 ±0.3 pA/µM (n=51 GluOX recording sites).
In a separate study, we examined MEA performance after in vivo recordings. The
post-implantation calibrations demonstrated that the parameters were not different (pre
vs. post-implantation, n=24 glutamate-oxidase recording sites, paired t-test): limit of
detection (1.1 ±0.1 µM vs. 1.5 ±0.4 µM, p=0.37), selectivity (93 ±21 vs. 83 ±26, p=0.77),
and slope (2.1 ±0.2 pA/µM vs. 2.2 ±0.1 pA/µM, p=0.68).
Oxygen is a required co-factor of glutamate-oxidase for the production of the
reporter molecule, H2O2. Therefore, we examined if low oxygen concentrations would
affect MEA performance. Glutamate responses were minimally affected by oxygen
concentration and the performance even at 0 µM oxygen was within 80% of the MEA
response obtained in air saturated buffer (200 µM).
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MEA/Micropipette Assembly
For local application of solutions in the rat brain, glass micropipettes (1 mm o.d.
0.58 mm i.d., A-M Systems, Inc., Everett, WA) were pulled (Kopf Instruments, Tujunga,
CA), and the tips of the micropipettes were bumped to create a tip with an i.d. of 10-15
µm. The micropipettes were placed centrally among all four platinum recording sites and
mounted 50-100 µm above the MEA. Micropipettes were filled with sterile filtered (0.20
µm) isotonic KCl solution (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2 or 120 mM KCl, 29
mM NaCl, 2.5 mM CaCl2, pH 7.4) concentrations previously used to elicit reproducible
KCl-evoked glutamate release in the brain regions of interest (Burmeister et al., 2002;
Day et al., 2006; Stephens et al., 2009). The micropipette was attached to a Picospritzer
III (Parker-Hannifin, Cleveland, OH) with settings adjusted to consistently deliver
volumes between 50-100 nl. Pressure was applied from 2-20 p.s.i. for 1 sec. Volume
displacement was monitored with the use of a stereomicroscope fitted with a reticule
(Friedemann and Gerhardt 1992).

In Vivo Anesthetized Recording
Two days after midline FPI, rats were anesthetized with urethane (1.25 g/kg i.p.)
(Sigma-Aldrich) and prepared for in vivo electrochemical recordings as previously
described (Burmeister, et al. 2002, Pomerleau, et al. 2003, Day, et al. 2006). Briefly,
animals were placed in a stereotaxic frame and body temperature was maintained at 37
°C with a water pad connected to a recirculating water bath. A craniotomy was
performed to provide access to the prefrontal cortex (AP: +3.2 mm, ML: +0.8 mm, DV:4.5 mm), dentate gyrus (AP: -4.3 mm, ML: +2.1 mm, DV -4.2), and striatum (AP: +1.0
mm, ML: +2.5 mm, DV: -4.0, -4.5, -5.0 mm) (Paxinos and Watson, 1998) (Fig 2.1C). A
Ag/AgCl reference wire was implanted into the lateral parietal cortex in the opposite
hemisphere from the recording areas. The MEA was lowered into the brain using a
microdrive (MO-10, Narishige International, East Meadow, NY). All MEA recordings were
performed at a frequency of 2 Hz using constant potential amperometry. After the MEA
reached a stable baseline (10-15 min), tonic glutamate levels (μM) were calculated by
averaging extracellular glutamate levels over 10 seconds. Local application of KCl
produced glutamate signals that were reproducible every 30 s. Each signal was
analyzed by the following parameters: amplitude (μM), T80 (s) the time for the signal to
decay by 80% from the peak amplitude, and k-1 (sec -1) the slope of the linear regression
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of the natural log transformation of the decay over time (Fig 2.1D) (Thomas, et al. 2009).
Approximately eight reproducible signals were evoked at each location and then
averaged into a representative signal for comparisons between injury groups. After
recording from all locations, a MEA with an attached micropipette was used to locally
apply green waterproof drawing ink (Higgins, Ebhard Faber Inc., Lewisburg, TN), which
was used to confirm MEA placement during brain sectioning.

Data Analysis
Amperometric data were analyzed using custom Microsoft Excel ™ - based
software to determine the tonic levels and KCl-evoked signal parameters. To determine
tonic levels of glutamate in the different brain regions, the background current from the
sentinel site was subtracted from the current of the glutamate-oxidase site. Then, the
resulting current (pA) was divided by the slope (µM/pA) obtained during the calibration to
determine the tonic glutamate concentration in a given brain region. Data from the
dentate gyrus and prefrontal cortex were analyzed by a one-way ANOVA followed by a
Bonferonni post-hoc test. For the striatum, data were analyzed by a repeated measures
two-way ANOVA followed by a Bonferonni post-hoc test (injury severity vs. depth). Data
are presented as mean ±SEM. Statistical significance was defined as p < 0.05.

Results

Prefrontal Cortex: Tonic and Evoked Glutamate Release
Tonic glutamate levels were not significantly changed in the prefrontal cortex two
days after mild or moderate diffuse brain injury [ANOVA: F(2,18)=0.8, p=0.43] (Fig 2.2A).
Tonic levels averaged 4.1 ±1.4 µM (sham), 4.2 ±1.3 µM (mild), and 6.2 ±2.5µM
(moderate). Local application of ~50 nL of 120 mM KCl produced reproducible glutamate
release in the prefrontal cortex. Representative recordings demonstrate similar evokedglutamate signals from local application of KCl between the sham and injury groups (Fig
2.2B). The amplitudes of KCl-evoked glutamate release in the prefrontal cortex were not
significantly changed after diffuse brain injury [ANOVA F(2,15)=0.49, p=0.62] (Fig 2.2C).
The amplitudes of KCl-evoked glutamate release in the sham, mild and moderate braininjured rats were 5 to 10 times larger than the corresponding tonic levels of glutamate.
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Amplitudes averaged 31.9 ±4.5 µM, 40.2 ±11.5 µM, and 27.8 ±9.6 µM in the sham, mild
and moderate brain-injured groups, respectively. Clearance parameters (T80 and k-1) of
the KCl-evoked glutamate signal back to tonic levels were equivalent between all groups
(Table 2.1). Thus, mild or moderate midline FPI did not produce significant changes in
the tonic glutamate concentration, the amplitude of KCl-evoked glutamate release, or
glutamate clearance parameters in the prefrontal cortex.

Dentate Gyrus: Tonic and Evoked Glutamate Release
Tonic glutamate levels in the hippocampal dentate gyrus were significantly
elevated after brain injury [ANOVA F(2,21)=4.9, p=0.018]. Tonic levels averaged 1.6
±0.4 µM (sham), 4.3 ±1.4 µM (mild), and 5.7 ±2.3 µM (moderate). Moderate brain-injured
animals exhibited a significant 256% increase in tonic glutamate levels compared to
sham controls (Fig 2.3A). Tonic glutamate levels in mild brain-injured animals were not
significantly different from either sham or moderate brain-injured animals. Local
application of ~75 nL of 70 mM KCl produced reproducible glutamate release in the
dentate gyrus. Representative recordings demonstrate similar evoked-glutamate signals
from local application of KCl between the sham and brain injury groups (Fig 2.3B).
Amplitudes of evoked-glutamate release in the dentate gyrus were not significantly
different between groups [ANOVA F(2,18)=0.41, p=0.67] (Fig 2.3C). The amplitude of
KCl-evoked glutamate release in the sham, mild and moderate injured rats were 4 to 15
times larger than the tonic glutamate levels, as amplitudes averaged 25.1 ±4.9 µM, 19.1
±4.9 µM, and 24.7 ±5.9 µM in the sham, mild and moderate brain-injured groups,
respectively. Clearance parameters (T80 and k-1) of the KCl-evoked glutamate signal
back to tonic levels were equivalent between all groups (Table 2.1). Thus, tonic levels of
extracellular glutamate were significantly increased after moderate midline FPI, with no
significant changes in the amplitude of KCl-evoked glutamate release or glutamate
clearance parameters in the dentate gyrus after mild or moderate midline FPI.

Striatum: Tonic and Evoked Glutamate Release
With the high spatial resolution of the platinum recording sites, glutamate
responses were sampled from multiple depths of the large heterogeneous structure of
the rat striatum (DV: -4.0 mm, -4.5 mm, -5.0 mm). Tonic glutamate levels were
significantly affected by brain injury severity [F(2,42)=9.26, p=0.0005] and by recording
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depth in the striatum [F(2,42)=4.87, p=0.0183]. At -4.0 mm in the striatum, tonic levels
averaged 2.3 ±0.6 µM (sham), 6.9 ±1.2 µM (mild) and 6.4 ±1.2 µM (moderate). Mild and
moderate brain injury produced a significant increase in tonic glutamate levels at a depth
of -4.0 mm compared to sham control animals, with a significant 200% increase after
mild brain injury and a significant 178% increase after moderate brain injury (Fig 2.4A).
The injury-induced increases in tonic glutamate levels after mild and moderate brain
injury compared to sham animals at recording depths of -4.5 mm and -5.0 mm did not
reach significance.
Local application of ~100 nL of 70 mM KCl produced reproducible glutamate
release in all depths of the striatum. Representative recordings of KCl-evoked glutamate
release in the dorsal striatum (-4.0 mm) demonstrate the significantly elevated amplitude
of glutamate release after moderate brain injury (Fig 2.4B). At -4.0 mm in the striatum,
the amplitude of KCl-evoked glutamate release were 10-25 times larger than the tonic
glutamate concentration, as amplitudes averaged 14.9 ±2.4 µM, 16.1 ±1.9 µM and 52.0
±16.6 µM in the sham, mild or moderate brain-injured animals, respectively. The
amplitude of evoked-glutamate release was significantly affected by brain injury severity
[F(2,42)=24.96, p<0.0001], but not by recording depth of the MEA [F(2,42)=0.02,
p=0.97]. Amplitudes of KCl-evoked glutamate release after moderate brain injury were
significantly elevated by 249%, 302%, 153% at -4.0, -4.5, and -5.0 mm, respectively (Fig
2.4C). Clearance parameters (T80 and k-1) of the KCl-evoked glutamate signal back to
tonic levels were equivalent in all depths of the striatum between all groups (Table 2.1).
Thus, the striatum exhibits significantly elevated tonic glutamate levels after mild and
moderate midline FPI, whereas the amplitude of KCl-evoked glutamate release was
elevated significantly only after moderate brain injury.

Tonic Glutamate Levels Correlate with Injury Force
To examine if injury force (atm) is predictive of tonic glutamate levels, linear
correlations were calculated for the three brain regions. The correlation was not
significant in the prefrontal cortex (Pearson r2=0.05 p=0.30). However, tonic glutamate
levels were significantly correlated with injury force in the dentate gyrus (Pearson
r2=0.29; p=0.006) and in the striatum, when the three recording depths were averaged
into a single value (Pearson r2=0.22; p=0.019) (Fig 2.5). Thus, injury force was predictive
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of elevated tonic glutamate levels in the dentate gyrus and the striatum at two days after
diffuse brain injury.
Discussion
We examined the extent of glutamate dysregulation two days after diffuse brain
injury, which may contribute to aberrant neuronal signaling and the propagation of
secondary injury cascades. The present study was a first attempt to use enzyme-based
MEAs to examine regional changes in glutamate signaling after TBI. First, the prefrontal
cortex exhibited no significant alterations in glutamate signaling two days after diffuse
injury. Second, tonic glutamate levels in the dentate gyrus and striatum were significantly
increased after midline FPI. Third, moderate midline FPI produced significant increases
in the amplitudes of evoked-glutamate release in multiple depths of the striatum. Finally,
tonic glutamate levels in the dentate gyrus and striatum were significantly correlated to
the mechanical forces of injury.
MEAs have improved upon some limitations inherent to microdialysis for
sampling glutamate in vivo. The high spatial resolution of the platinum recording sites
allowed glutamate measurements from discrete regions, which is vital in studying local
glutamate regulation. Also, the 2 Hz sampling rate of the MEAs records the fast
dynamics of glutamate signaling that may be susceptible to TBI pathophysiology. The
improved spatial resolution and limited damage to the surrounding tissue (Rutherford, et
al. 2007) allow MEAs to sample glutamate spillover from nearby synapses that are TTX
sensitive (Day, et al. 2006, Hascup, et al. 2008). In contrast, microdialysate samples of
glutamate are largely TTX independent and poorly correlated with the concentration of
glutamate near synapses (Timmerman and

Westerink 1997, Obrenovitch 1999).

Moreover, the small recording sites of the MEAs require little tissue oxygen utilization
and the electrochemical oxidation of H2O2 produces oxygen as supplementary substrate
for glutamate-oxidase. In anoxic tissue, such as stroke, MEA performance may be
compromised.
Tonic glutamate levels in the dentate gyrus and striatum are positively correlated
with injury severity. However, the concentrations do not appear to reach excitotoxic
levels, as a continuous infusion of 1.8 M glutamate at 0.5 µL/hr was insufficient to
produce a neuropathological lesion (Mangano and Schwarcz 1983). The present study
was carried out under urethane anesthesia, which can decrease tonic glutamate levels
by 60-80% (Rutherford, et al. 2007). Therefore, the values reported here may represent
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only a fraction of the tonic glutamate concentration in the awake animal. Still, the
increased tonic glutamate levels may contribute to the development or maintenance of
diffuse brain injury pathophysiology. The observed tonic glutamate levels may explain
elevated neuronal calcium levels, altered calcium regulation, which result in calpain
mediated spectrin proteolysis reported after midline FPI (Sun, et al. 2008, McGinn, et al.
2009). With regard to secondary injuries, increased tonic glutamate levels after the initial
injury may produce increased susceptibility to excitotoxic damage or provide
neuroprotection via preconditioning. Future work should examine the effect of increased
tonic glutamate levels on a secondary insult and identify alternate sources of glutamate
contributing to the increased tonic glutamate levels.
Tonic glutamate levels seem independent of evoked-glutamate release as we
report significant increases in tonic glutamate levels in the presence and absence of
alterations in KCl-evoked glutamate release, depending on brain region. Evokedglutamate release, unlike the graded response in tonic glutamate levels, exhibited an allor-none response with injury severity. Local application of isotonic KCl depolarized local
axons and pre-synaptic terminals, evoking neurotransmitter release. The increase in
extracellular glutamate was transient as glutamate uptake rapidly restores the glutamate
concentration back to tonic levels. Although transient, elevated evoked-glutamate
release may prolong secondary injury cascades, by excessively activating ionotropic
receptors, increasing calcium influx, and activating proteases (McIntosh, et al. 1996).
Elevated evoked-glutamate release could arise from several different mechanisms. First,
the pre-synaptic terminal could release more glutamate vesicles or vesicles with higher
glutamate concentrations. Lateral FPI produces transient changes in the synaptic
machinery, specifically complexin I and II, up to one week after injury, which could alter
neurotransmitter packaging and synaptic release (Yi and Hazell 2006). Furthermore,
free radicals can increase KCl-evoked glutamate release (Pellegrini-Giampietro, et al.
1990). Second, reduced glutamate transporter function would increase the extracellular
glutamate concentration. Controlled cortical impact decreases the expression of GLT-1
and GLAST, the EAATs which mediate most of the glutamate uptake in the rat brain
(Rothstein, et al. 1996, Rao, et al. 1998). Third, synaptic reorganization may alter
synaptic structure and function. Future work could explore clearance of locally applied
glutamate into the extracellular space to evaluate EAATs surface expression (Nickell, et
al. 2007).
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Midline FPI produces a diffuse, multi-focal pathology with significant neurological
impairments after mild and moderate injury, without overt cavitation (McIntosh, et al.
1987, Schmidt and

Grady 1993, Hamm 2001, Kelley, et al. 2007). In addition,

physiological disturbance may contribute to observed post-traumatic deficits (Lyeth, et
al. 1990, Delahunty, et al. 1995). The spectrum of deficits includes behavioral, cognitive
and motor impairments ascribed to the prefrontal cortex, hippocampus, and striatum
(Baddeley 1992, Capruso and Levin 1992, McAllister 1992, Levine, et al. 2002, Khan, et
al. 2003).
The medial prefrontal cortex receives glutamatergic projections from the
mediodorsal nucleus of the thalamus, hippocampus, and amygdala (Steketee 2003).
Post-traumatic impairments in working memory have been linked to damage in the
medial prefrontal cortex (Baddeley 1992, Delatour and Gisquet-Verrier 2000, Levine, et
al. 2002). Here, we report no significant changes in tonic glutamate levels or evoked
glutamate release in the medial prefrontal cortex, likely due to the injury type or the
selected time point. Few reports have examined the prefrontal cortex after midline FPI,
reporting blood-brain barrier disruption within 24 hours post-injury (McIntosh, et al. 1987,
Schmidt and

Grady 1993). After controlled cortical impact, impairments in working

memory have been attributed to excessive GABA-meditated inhibition weeks post-injury
(Kobori, et al. 2006, Kobori and Dash 2006). Thus, diffuse brain injury in the medial
prefrontal cortex retains glutamate regulation at two days post-injury.
The dentate gyrus of the hippocampus receives glutamate projections from the
entorhinal cortex and projects to area CA3 (Andersen 2007). Survivors of TBI suffer from
impairments in learning and memory attributed to hippocampal damage (Tate and Bigler
2000). Midline FPI produces significant deficits in the Morris water maze memory tests
11-15 days after injury (Hamm, et al. 1993, Liu, et al. 1994). In the absence of significant
neuronal cell death, physiological changes in the hippocampus may contribute to the
functional deficits (Lyeth, et al. 1990, Delahunty, et al. 1995, Grady, et al. 2003). The
significantly elevated tonic glutamate levels after moderate brain injury may provide a
potential substrate for the increased hippocampal excitability reported two days after
midline FPI (Reeves, et al. 1995) and ensuing cognitive deficits.
The striatum receives glutamatergic projections from the thalamus and virtually
all regions of the neocortex (Fonnum, et al. 1981). Survivors of TBI suffer motor and
cognitive impairments (Khan, et al. 2003), as reported with glutamate and dopamine
dysregulation in the striatum (Canales, et al. 2002). Injury-induced increases in tonic and
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evoked-glutamate release in the striatum at two days post-injury may underlie the motor
deficits within five days post-injury and the memory deficits within 11-15 days post-injury
(Liu, et al. 1994, Hamm 2001). Two weeks after controlled cortical impact, dopamine
neurotransmission in the striatum exhibited decreased electrically-induced dopamine
overflow, decreased levels of the dopamine transporter, and decreased dopamine
uptake from the extracellular space (Wagner, et al. 2005). Activation of ionotropic
glutamate receptors reduces evoked-dopamine release in the striatum (Wu, et al. 2000).
The glutamate-dopamine interactions underlying motor and cognitive function warrant
further investigation to explain the neurological deficits observed in experimental and
clinical TBI.
In conclusion, we used MEAs in combination with midline FPI to examine how
diffuse brain injury alters glutamate signaling without the influence of tissue destruction
seen in focal injury models. Our results demonstrate that elevated glutamate signaling
contributes to the pathophysiology of diffuse brain injury, establishing a basis for further
functional deficits. The specific mechanisms responsible for the elevations in tonic
glutamate levels and evoked-glutamate release in vivo should be explored over a more
complete time course to identify novel therapeutic targets to improve outcomes after TBI.
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This is a copy of an article published in the [Journal of Neurotrauma] © [2010] [copyright
Mary Ann Liebert, Inc.]; [Journal of Neurotrauma] is available online at:
http://online.liebertpub.com.
Copyright © Jason Michael Hinzman 2012
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Chapter Two: Figures

Figure 2.1 Methods for microelectrode array glutamate recordings
(A) Schematic diagram showing the configuration and coatings applied to the MEA. The
lower pair of platinum sites were prepared with a mixture of glutamate-oxidase (GluOX),
bovine serum albumin (BSA), and glutaraldehyde (Glut), illustrated at left. While the
upper pair of platinum sites were prepared only with BSA and Glut, illustrated at right. A
layer of m-phenylenediamine (mPD) is electroplated onto the recording sites providing a
size exclusion layer to block major interferents, ascorbic acid (AA) and dopamine (DA).
(B) MEA in vitro calibration measuring the change in current on a GluOX site (solid line)
and a sentinel site (dashed line) with addition of multiple analytes
↑). Additions
(
of
interferents such as AA and DA produced no change in current on the GluOX or sentinel
sites. Three glutamate (Glu) additions showed a stepwise increase of current on the
GluOX site with no response on the sentinel site. Addition of H2O2 produces an increase
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in current on both the GluOX and sentinel sites. (C) Illustrations of coronal sections of
the rat brain (Paxinos and Watson, 1998) highlight the regions of interest for glutamate
recordings (*)in the prefrontal cortex (PFC, AP: 3.2 mm), striatum (STR, AP: 1.0 mm),
and dentate gyrus (DG, AP: -4.3 mm). (D) Representative in vivo recording from a
GluOX site and sentinel site. Local application of KCl ↑( ) produced reproducible
glutamate release, highlighting the fast kinetics of glutamate release and uptake. Tonic
glutamate was calculated in each brain region after the microelectrode had reached a
stable baseline. KCl-evoked glutamate release was analyzed using the following
parameters: amplitude, T80, and k-1 for each signal. Parameters are shown separately for
clarity.
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Figure 2.2 Tonic and KCl-evoked release of glutamate in the prefrontal cortex of
the urethane anesthetized rat
(A) Tonic glutamate levels were not significantly different after mild or moderate midline
FPI (n= 7). (B) Baseline-matched representative recordings exhibit no significant change
in KCl-evoked glutamate release after midline FPI. Local application of KCl (↑) produced
a robust increase in extracellular glutamate that rapidly returned to tonic levels. (C) The
average amplitudes of KCl-evoked glutamate release were not significantly different after
mild or moderate midline FPI (n= 6).
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Figure 2.3 Tonic and KCl-evoked release of glutamate in the dentate gyrus in the
hippocampus of the urethane anesthetized rat
(A) Tonic glutamate levels were significantly increased after moderate midline FPI in the
dentate gyrus (* p< 0.05, n= 8). (B) Baseline-matched representative recordings exhibit
no significant change in KCl-evoked glutamate release after midline FPI. (C) The
average amplitudes of KCl-evoked glutamate release were not significantly different after
mild or moderate injury (n= 7).
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Figure 2.4 Tonic and KCl-evoked release of glutamate in the striatum of the
urethane anesthetized rat
(A) Tonic glutamate levels were significantly increased after mild or moderate injury in
the striatum at a depth of -4.0 mm with no significant changes at -4.5 mm or -5.0 mm (*
p< 0.05, n= 8). (B) Baseline-matched representative recordings of KCl-evoked glutamate
release showed that there was a significant increase in the amplitude of glutamate
release after moderate midline FPI. Local application of KCl↑) ( produced a robust
increase in extracellular glutamate that rapidly returned to tonic levels. (C) The average
amplitudes of KCl-evoked glutamate release in the rat striatum at -4.0 mm, -4.5 mm, -5.0
mm were significantly increased after moderate midline FPI from local application of 100
nL of 70 mM KCl, compared to sham or mild injury animals (* p< 0.05, ** p< 0.01, n= 8).
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Figure 2.5 Correlations of tonic glutamate levels with force of injury in the rat
prefrontal cortex, dentate gyrus, and striatum
Tonic glutamate levels were not significantly correlated with injury force in the prefrontal
cortex (n= 7), but were significantly correlated in the dentate gyrus (** p < 0.01, n= 8),
and in the striatum (* p < 0.05, n= 8).
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Chapter Two: Tables

Table 2.1 Clearance Parameters of KCl-Evoked Glutamate Release
k -1 (sec-1)

T 80 (sec)
Sham

Mild

Moderate

Sham

Mild

Moderate

Prefrontal Cortex

7.0 ±0.6

8.7 ±1.5

7.4 ±1.6

0.11 ±0.02

0.11 ±0.02

0.15 ±0.01

Dentate Gyrus

5.5 ±0.8

7.1 ±1.3

5.6 ±0.6

0.17 ±0.03

0.17 ±0.03

0.16 ±0.05

Striatum (-4.0 mm)

5.4 ±0.4

6.0 ±0.6

6.9 ±0.8

0.14 ±0.02

0.14 ±0.03

0.13 ±0.02

Striatum (-4.5 mm)

4.3 ±0.3

5.3 ±1.2

5.1 ±0.8

0.21 ±0.04

0.19 ±0.05

0.25 ±0.02

Striatum (-5.0 mm)

4.4 ±0.6

5.9 ±1.5

5.9 ±1.1

0.27 ±0.06

0.18 ±0.04

0.21 ±0.03

Mean ±SEM; Prefrontal Cortex n= 6; Dentate Gyrus n= 7; Striatum n= 8
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Preface to Chapter Three

The aim of the experiments in Chapter Three was to examine how neurons and
glia regulate extracellular glutamate to determine the source of increased extracellular
glutamate after diffuse traumatic brain injury. Using glutamate-sensitive microelectrode
arrays (MEAs) coupled with targeted pharmacological agents, I developed a model on
the regulation of extracellular glutamate by neurons and glia. Furthermore, I detected
disruptions in the release and regulation of extracellular glutamate by both neurons and
glia after diffuse brain injury. Overall, this study uncovers specific targets to try to
improve the regulation of extracellular glutamate with therapeutics after TBI.

Chapter Three: Disruptions in the Regulation of Extracellular Glutamate by
Neurons and Glia in the Rat Striatum Two Days after Diffuse Brain Injury

Abstract
Disrupted regulation of extracellular glutamate in the central nervous system
contributes to and can exacerbate the acute pathophysiology of traumatic brain injury
(TBI). Previously, we reported increased extracellular glutamate in the striatum of
anesthetized rats at two days after diffuse brain injury. To determine the mechanism(s)
responsible

for

increased

extracellular

glutamate,

we

used

enzyme-based

microelectrode arrays (MEAs) coupled with specific pharmacological agents targeted at
in vivo neuronal and glial regulation of glutamate. After TBI, extracellular glutamate was
significantly increased in the striatum by ~90% averaging 4.1 ±0.6 µM compared to
sham 2.2 ±0.4 µM. Calcium-dependent neuronal glutamate release, investigated by local
application of a N-type calcium channel blocker, was no longer a significant source of
extracellular glutamate after TBI compared to sham. In brain-injured animals, inhibition
of glutamate uptake with local application of an excitatory amino acid transporter
inhibitor produced significantly greater increase in glutamate spillover (~65%) from the
synapses of brain-injured animals compared to sham. Furthermore, glutamate clearance
measured by locally applying glutamate into the extracellular space revealed significant
reductions in the glutamate clearance parameters in brain-injured animals compared to
sham. Taken together, these data indicate disruptions in calcium-mediated glutamate
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release and glial regulation of extracellular glutamate contribute to increased
extracellular glutamate in the striatum two days after diffuse brain injury. Overall, these
data suggest that therapeutic strategies used to regulate glutamate release and uptake
may improve excitatory circuit function and possibly outcomes following TBI.

Introduction
The central nervous system requires strict regulation of extracellular glutamate to
guard against aberrant neuronal signaling and possible excitotoxicity. Disrupted
glutamate regulation plays a pivotal role in the acute pathophysiology of traumatic brain
injury (TBI) through the initiation of secondary injury cascades (McIntosh, et al. 1996,
Bullock, et al. 1998). The primary physical and mechanical forces of a TBI disrupt the
blood-brain barrier and cellular membranes leading to a release of intracellular contents
into the extracellular space (Schmidt and

Grady 1993, Bullock, et al. 1998).

Furthermore, disruptions in ionic regulation after TBI create a massive depolarization or
wave of depolarizations that promotes excessive neuronal glutamate release
(Katayama, et al. 1990). Moreover, post-traumatic reductions in the expression of
excitatory amino acid transporters (EAATs) responsible for removing glutamate from the
extracellular space leads to further increases in extracellular glutamate levels (Rao, et al.
1998, van Landeghem, et al. 2001, Yi, et al. 2005, van Landeghem, et al. 2006, Yi and
Hazell 2006). High extracellular glutamate propagates secondary injury cascades
through the activation of glutamate receptors, increasing ionic flux, disrupting ionic
homeostasis, activating calcium-dependent proteases and phospholipases, uncoupling
ATP synthesis, and producing reactive oxygen species (Faden, et al. 1989, Hall, et al.
1994, McIntosh, et al. 1996, Yi and Hazell 2006).
Glutamate is normally released into the extracellular space by both neuronal and
non-neuronal sources (Jabaudon, et al. 1999, Jensen, et al. 2000). Once in the
extracellular space, glutamate binds to both ionotropic glutamate receptors and
metabotropic glutamate receptors (mGluRs) for signal propagation. For removal of
glutamate from the extracellular space, five high affinity sodium-dependent excitatory
amino acid transporters (EAATs), GLAST, GLT-1, EAAC, EAAT4, and EAAT5, are
expressed throughout the central nervous system (Danbolt 2001). Glutamate uptake is
driven by electrochemical gradients across neurons and glia with the majority (~90%) of
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glutamate uptake performed by two glial transporters in the rat striatum, GLAST and
GLT-1 (Rothstein, et al. 1996, Tanaka, et al. 1997, Danbolt 2001).
Clinically, a multitude of studies have detected significant increases in
extracellular glutamate levels in the days following injury with some reports correlating
increases in extracellular glutamate with unfavorable outcomes (Persson and Hillered
1992, Bullock, et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 1998,
Yamamoto, et al. 1999, Reinert, et al. 2000, Hutchinson, et al. 2002, Hlatky, et al. 2004,
Chamoun, et al. 2010, Lakshmanan, et al. 2010, Timofeev, et al. 2011a). These studies
emphasize the significance of glutamate dysregulation in the acute pathophysiology and
consequences of TBI. Unlike the clinical studies, multiple animals studies report
increases in extracellular glutamate at the time of the injury, which returns to baseline
concentrations within a few hours (Faden, et al. 1989, Katayama, et al. 1990, Nilsson, et
al. 1990, Palmer, et al. 1993, Globus, et al. 1995, Katoh, et al. 1997, Stoffel, et al. 1997,
Matsushita, et al. 2000, Rose, et al. 2002, Stoffel, et al. 2002). Because experimental
TBI has failed to model glutamate dysregulation seen in the clinic, the role of glutamate
excitotoxicity in the acute pathophysiology of TBI has been challenged and remains
unclear (Carbonell and Grady 1999, Obrenovitch 1999).
Using

novel

enzyme-based

microelectrode

arrays

(MEAs)

to

measure

extracellular glutamate, we previously reported significant increases in extracellular
glutamate and evoked glutamate release in the striatum two days after midline fluid
percussion brain injury (Hinzman, et al. 2010). The purpose of this study was to examine
the regulation of extracellular glutamate by both neurons and glia to identify specific
mechanism(s) responsible for the increased extracellular glutamate in the rat striatum
two days after diffuse brain injury. Using targeted pharmacological agents, we examined
how both neurons and glia release and regulate extracellular glutamate. First, we
examined the contribution of calcium-mediated neuronal glutamate release to
extracellular glutamate by locally applying an N-type calcium channel blocker (ωconotoxin). Second, we examined if transient activation of the group II mGluRs
(mGluR2/3) would improve neuronal regulation of extracellular glutamate by locally
applying a mGluR2/3 agonist (LY 379268). Third, we examined non-neuronal sources of
extracellular glutamate such as the glial expressed cystine/glutamate exchanger (xc-) by
locally applying a xc- blocker ((S)-4-carboxyphenylglycine: CPG). Fourth, we examined
how glia regulate extracellular glutamate by inhibiting glutamate uptake with a
competitive non-transportable EAATs blocker (D,L-threo-β-benzyloxyaspartate: TBOA).
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Finally, we directly tested the ability of glia to clear glutamate from the extracellular
space.

Materials and Methods

Animals
Male Sprague-Dawley rats (300-400g; Harlan Laboratories Inc., Indianapolis, IN)
were used for all experiments (n =45). The animals were housed in a 12 h light/dark
cycle with food and water available ad libitum according to the Association for
Assessment and Accreditation of Laboratory Animal Care International. Animals were
acclimated to their environment for at least one week before any experiments. After
surgery, animals were evaluated daily for post-operative care by a physical examination
of the rat screening the animals breathing, gait, coat appearance, dehydration, body
appearance, locomotion, and food and water intake. Animal care was approved by the
University of Kentucky Institutional Animal Care and Use Committee.

Midline fluid percussion injury (FPI)
Animals were subjected to midline FPI as previously described (Lifshitz 2008,
Hinzman, et al. 2010, Thomas, et al. 2011). Rats were initially anesthetized with
isoflurane at 5% for five minutes and placed in a stereotaxic frame in a sterile surgery
hood with continuously delivered isoflurane at 2%. The head was shaved and a 70%
alcohol and betadine solution was applied to the skin. Eyes were treated with artificial
tears and body temperature was maintained with a delta-phase heating pad at ~37oC
(Braintree Scientific, Braintree, MA). A midline incision was made and fascia removed
from the skull. A 4.7 mm trephine was used for the craniotomy, centered on the sagittal
suture between bregma and lambda without disrupting the underlying dura or superior
sagittal sinus. Anchoring screws were secured into pilot holes remote from the
craniotomy. An injury hub was constructed from a Luer-Loc hub (20 gauge needle). The
outer diameter of the hub was beveled to match the craniotomy. The injury hub was
fitted into the craniotomy and cyanoacrylate gel was applied to seal the skull-hub
interface. To secure the injury hub to the anchoring screws, methyl-methacrylate
(Hygenic Corp., Akron, OH) was applied. The hub was filled with sterile saline and the
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wound sutured to prevent tearing. The female Luer-Loc injury hub was connected to the
male Luer-Loc hub of the injury device (Custom Design and Fabrication, Virginia
Commonwealth University, Richmond, VA). Before reflexive responses returned, the
pendulum hammer of the injury device was dropped onto the fluid-filled piston to induce
a moderate injury. Sham injured animals underwent the same procedure without
induction of injury. The fluid pressure pulse for the brain injury was 2.0 ± 0.01 atm. The
injury hub was removed and any bleeding controlled with Gelfoam (Pharmacia,
Kalamazoo, MI). The incision was closed with staples. Righting reflex recovery times
were recorded for the injury group, from the time of impact to the time when animals’
spontaneously righted. Brain injured animals had righting times of 437 ±19 seconds (n
=23). Sham injured animals had righting reflex less than 15 seconds (n =22). No animals
died from complications caused by the injury.

Enzyme-based microelectrode arrays
Ceramic-based MEAs, consisting of four platinum recording sites (15 x 333 µm)
arranged vertically in dual pairs, were prepared and selected for in vivo recordings as
previously described (Burmeister, et al. 2002, Day, et al. 2006, Hascup, et al. 2007,
Stephens, et al. 2009, Hinzman, et al. 2010). Briefly, a glutamate-oxidase solution
covered one pair of recording sites to allow for the enzymatic conversion of glutamate to
α-ketoglutarate and the generation of the reporter molecule, H2O2. The small amount of
H2O2 generated by glutamate-oxidase on the surface of the MEA will have a minimal
impact on the production of reactive oxygen species in the local area due to the small
amount of glutamate-oxidase coated on the surface of the MEA, the oxidation of H2O2 by
the MEA, and the limited time of the MEA in the tissue. An inactive protein matrix
covered the other pair of recording sites (sentinel sites). The two different coatings
allowed the use of a self-referencing technique, in which the background current of the
sentinel sites could be subtracted from the current of the glutamate-oxidase sites,
thereby producing a more selective glutamate measure allowing the determination of
tonic levels of glutamate (Burmeister and

Gerhardt 2001, Burmeister, et al. 2002).

Furthermore, a size exclusion layer of 1,3–phenylenediamine (mPD) was electroplated
onto the platinum recording sites to restrict the passage of large molecule interferents
(ascorbic acid and dopamine) from reaching the platinum recording sites to further
improve the selectivity of the MEA’s for glutamate detection (Hinzman, et al. 2010).

39

MEA calibration
Constant potential amperometry was performed with the MEAs using the FAST16 mkII system (Quanteon Inc., LLC, Nicholasville, KY). A potential of +0.7 V versus an
Ag/AgCl reference was applied to oxidize the reporter molecule, H2O2. The resulting
current was amplified and digitized by the FAST-16 mkII system. Calibrations were
conducted to test the capability of the MEA to selectively measure glutamate and to
generate a standard curve for the conversion of current to concentration of glutamate.
The parameters tested were limit of detection (three times the standard deviation of the
baseline noise), selectivity (ability of the MEA to measure glutamate compared to a
major interferent, ascorbic acid), and slope of the electrode (the linear increase in
current due to additions of glutamate). The average limit of detection was 0.99 ±0.1 µM,
selectivity was 301 ±57 (glutamate: ascorbic acid), and slope was 8.7 ±0.6 pA/µM
(n=113 glutamate recording sites).

Calibrations were conducted before in vivo

experimentation to ensure MEAs were functional before implantation and prior results
have shown similar performance of the MEAs between pre- and post-experimental
testing (Hinzman, et al. 2010).

MEA/micropipette assembly
For local application of solutions into the rat brain, glass micropipettes (1 mm o.d.
0.58 mm i.d., A-M Systems, Inc., Everett, WA) were pulled (Kopf Instruments, Tujunga,
CA), and the tips of the micropipettes were bumped to create a tip with an i.d. of 10-15
µm. The micropipettes were placed centrally among all four platinum recording sites and
mounted 50-100 µm above the MEA. Micropipettes were filled with (1) 10 µM ωconotoxin GVIA, N-type calcium channel blocker, (Alomone Labs, Jerusalem, Israel); (2)
100 µM LY 379268, mGluR

2/3

receptor agonist, (Tocris, Ellisville, MO); (3) 50 µM (S)-4-

carboxyphenylglycine (CPG), xc- blocker, (Tocris, Ellisville, MO); (4) 100 µM

D,L-threo-β-

benzyloxyaspartate (TBOA), EAATs competitive inhibitor, (Tocris, Ellisville, MO); (5)
500 µM glutamate (Sigma-Aldrich, St. Louis, MO); or (6) physiological saline (Day, et al.
2006, Hascup, et al. 2010). All drugs were dissolved to their final concentrations in
physiological saline. Solutions were sterile filtered (0.20 µm) and adjusted to a pH of 7.4.
The micropipette was connected to a Picospritzer III (Parker-Hannifin, Cleveland, OH)
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with settings adjusted to consistently deliver volumes between 12.5-350 nL. Pressure
was applied from 2-30 psi for 0.3-3 sec. Volume displacement was monitored with the
use of a stereomicroscope fitted with a reticule to determine and control the volume of
solution that was locally applied by pressure ejection. (Friedemann and Gerhardt 1992).

In vivo anesthetized recordings of extracellular glutamate
Two days after midline FPI, rats were anesthetized with urethane (1.25 g/kg i.p.)
(Sigma-Aldrich) and prepared for in vivo electrochemical recordings as previously
described (Day, et al. 2006, Hascup, et al. 2007, Stephens, et al. 2009, Thomas, et al.
2009, Hinzman, et al. 2010, Thomas, et al. 2011). Briefly, animals were placed in a
stereotaxic frame and body temperature was maintained at ~37 °C with a water pad
connected to a recirculating water bath. A craniotomy was performed to provide access
to the striatum (AP: +1.0 mm, ML: +/- 2.5 mm, DV: -3.5, -4.0, -4.5, -5.0 mm), (Paxinos
and Watson, 1998). A Ag/AgCl reference wire was implanted into the lateral parietal
cortex. The MEA was lowered into the brain using a microdrive (MO-10, Narishige
International, East Meadow, NY). All MEA recordings were performed at a frequency of
2 Hz.
To measure tonic extracellular glutamate, the background current from the
sentinel site was subtracted from the current of the enzyme site. Then, the resulting
current (pA) was converted to glutamate concentration by dividing the current by the
slope (pA/µM) obtained during the calibration. To examine the effect of drugs on
extracellular glutamate, 100 nL of physiological saline was locally applied to assess
potential dilution effects. Then, the solution in the micropipette was exchanged and 100
nL of the drug of interest was locally applied into the striatum using the same application
parameters. The maximum increase/decrease in extracellular glutamate and area
above/below the curve (to examine the extent of changes in extracellular glutamate with
respect to time) were calculated for both local application of saline and the drugs of
interest. To examine glutamate clearance, varying volumes of 500 µM glutamate were
applied into the extracellular space. Glutamate signals with amplitudes in the 5-50 μM
range were analyzed as this was the physiological range of KCl-evoked glutamate
release seen in sham and brain injured rats (Hinzman, et al. 2010). Glutamate clearance
was analyzed for the following parameters: (1) amplitude (μM); (2) Trise (s), the time for
the signal to reach the peak amplitude; (3) T80 (s), the time for the signal to decay by
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80% from the peak amplitude; (4) and k-1 (sec -1), the slope of the linear regression of the
natural log transformation of the decay over time (Nickell, et al. 2007, Thomas, et al.
2009, Hinzman, et al. 2010).

Quantitative gene expression (rtPCR)
Two days post-injury, sham and brain-injured animals were transcardially
perfused with cold saline, the brains rapidly removed from the skull, dissected into 2 mm
slices using a chilled rat brain matrix, and a 1 mm diameter biopsy was removed from
the dorsal striatum. The mRNA content was stabilized (RNAlater, Qiagen Corp) and
stored frozen. Isolated mRNA (RNeasy, Qiagen Corp) was quantified (NanoDrop ND1000 spectrophotometer), converted to complementary DNA (cDNA; High Capacity
cDNA Archive Kit, Applied Biosystems Inc.) and then used as a template for selected
commercially-available gene expression assays for quantitative real-time PCR
(StepONE, Applied Biosystems). The Applied Biosystems TaqMan® Gene Expression
Assays (GLT-1: Rn00568080_m1; GLAST: Rn00570130_m1; 18s rRNA: 4352930E)
were used for EAAT gene expression. Within each animal, relative gene expression was
normalized to the 18s rRNA endogenous control and the expression level in the
sham/vehicle group using the 2-ΔΔCT method (Livak and Schmittgen 2001), which relates
gene expression to the PCR cycle number at which the fluorescence signals exceed a
threshold above baseline. Relative gene expression was compared between sham and
brain-injured animals using a two-tailed t-test.
Statistical analyses
Amperometric data were analyzed using custom MATLAB® - based software. For
both resting extracellular glutamate and analysis of glutamate clearance, multiple depths
in the striatum were averaged per animal as there were no sub-regional differences
detected. All data were analyzed using a two-tailed t-test. Data are presented as mean ±
SEM, and statistical significance was defined as p < 0.05.

Results
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Increased extracellular glutamate in the striatum of brain-injured rats
Previously, our laboratory has reported increased extracellular glutamate in the
striatum two days after midline fluid percussion injury (Hinzman, et al. 2010). Here, we
confirm the original finding detecting significantly higher extracellular glutamate after TBI
than in sham [t30 = 2.681, p = 0.012] (Fig 3.1). Extracellular glutamate averaged 2.2 ± 0.4
µM (Sham) vs. 4.1 ± 0.6 µM (TBI). Since we detected significant increases in
extracellular glutamate after TBI, we set out to pharmacologically manipulate the
regulation of glutamate by both neurons and glia to determine the possible
mechanism(s) responsible for the increased extracellular glutamate after TBI.

Reduced calcium channel-dependent glutamate release in the striatum of
brain-injured rats
By applying a N-type calcium channel blocker (ω-conotoxin) into the extracellular
space, we examined the contribution of calcium-mediated vesicular glutamate release
on extracellular glutamate. In sham, local application of ω-conotoxin produced a
significant (~80 %) decrease in extracellular glutamate and reduced glutamate for a
longer period of time (area under curve) compared to local application of saline (Table
3.1). After TBI, local application of ω-conotoxin failed to reduce the extracellular
glutamate concentration compared to local application of saline (Table 3.1). Averaged
group responses to the local application of ω-conotoxin into the striatum in both sham
and TBI groups demonstrate the reduced efficacy of ω-conotoxin on reducing
extracellular glutamate after TBI (Fig 3.2A). The maximum decrease in extracellular
glutamate in the presence of ω-conotoxin was significantly smaller after TBI compared to
sham [t6 = 2.901, p = 0.028] (Fig 3.2B). Also, the extent of reduced glutamate with
respect to time (area under curve) was significantly reduced after TBI as compared to
sham [t6 = 3.113, p = 0.021] (Fig 3.2C). Thus, in sham animals calcium-mediated
neuronal glutamate release was a significant source to extracellular glutamate.
Whereas, calcium-mediated neuronal glutamate release was no longer a significant
source to extracellular glutamate in brain-injured animals. Consequently, increased
calcium-dependent glutamate release is unlikely to be a predominant mechanism for
increased extracellular glutamate after TBI.
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Activation of mGluR2/3 failed to reduce extracellular glutamate in the
striatum of sham and brain-injured rats
Additional studies were carried out to investigate other potential presynaptic
changes in glutamate regulation after TBI. By applying an mGluR2/3 agonist (LY 379268)
into the extracellular space, we examined if transient activation of the glutamate
autoreceptors, mGluR2/3, would reduce neuronal glutamate release and thereby improve
regulation of extracellular glutamate. Local application of LY 379268 failed to produce a
significant decrease in extracellular glutamate compared to local application of saline in
sham and after TBI (data not shown). Thus, insufficient mGluR2/3 activation is unlikely to
be responsible for increased extracellular glutamate after TBI.

Inhibition of the glial xc- failed to reduce extracellular glutamate in the
striatum of sham and brain-injured rats
Another glial source of extracellular glutamate may be derived from the xc-,
predominantly localized to glia. Considerable attention has recently been paid to the xcand its possible role in glutamate dysregulation by glia in drug abuse (Kalivas 2009). By
applying a xc- blocker (CPG) into the extracellular space, we examined the contribution
of glutamate release through the xc- on extracellular glutamate. Local application of CPG
failed to produce a significant decrease in glutamate compared to local application of
saline in sham and after TBI (data not shown). Thus, glial glutamate release through the
xc- is not a significant source of extracellular glutamate in sham and TBI animals, and
glutamate release through the xc- unlikely to be a mechanism for increased extracellular
glutamate after TBI.

Increased glutamate spillover from the inhibition of glutamate uptake in the
striatum of brain-injured rats
We further examined if disruptions in the regulation of extracellular glutamate by
glia were responsible for the increased extracellular glutamate after TBI. Glutamate
uptake through the EAATs, predominantly localized to glia, is the primary mechanism for
regulating extracellular glutamate. By locally applying a competitive non-transportable
EAAT blocker (TBOA) into the extracellular space, we examined how transient inhibition
of glutamate uptake alters the extracellular glutamate concentration. In sham, local
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application of TBOA produced a rapid and significant increase in the extracellular
glutamate concentration and produced higher levels of glutamate for a longer period of
time (area under curve) compared to local application of saline (Table 3.1). After TBI,
local application of TBOA produced a rapid and significant increase in the extracellular
glutamate concentration and produced higher levels of glutamate for a longer period of
time (area under curve) compared to local application of saline (Table 3.1). Averaged
group responses from the local application of TBOA within the striatum in both sham and
TBI groups demonstrate increased amounts of glutamate spillover from inhibition of
glutamate uptake after TBI (Fig 3.3A). The maximum increase in extracellular glutamate
from local application of TBOA was significantly greater after TBI than sham [t6 = 3.391,
p = 0.015] (Fig 3.3B). Also, after TBI more glutamate remained in the extracellular space
for a longer period of time (area under curve) than in sham [t6 = 2.521, p = 0. 045] (Fig
3.3C). Thus, the increased glutamate spillover from the transient inhibition of glutamate
uptake in brain-injured animals suggests decreased glutamate uptake may play a role in
the increase in extracellular glutamate after TBI.
Using quantitative real-time PCR, we examined if decreased gene expression of
glial EAATs (GLAST and GLT-1) was responsible for the increased sensitivity to the
inhibition of the EAATs to TBOA. In the dorsal striatum, the relative expression of
GLAST and GLT-1 was decreased, but not significantly after TBI compared to sham;
(sham: TBI), GLAST (1.02 ± 0.13: 0.80 ± 0.06) [t6 = 1.58, p = 0.164], GLT-1 (1.01 ± 0.06:
0.84 ± 0.16) [t6 = 0.95, p = 0.378]. Thus, any injury-related changes in glial glutamate
transporters are not evident as changes in gene expression.

Decreased glutamate clearance in the striatum of brain-injured rats
We further explored post-traumatic decreases in glutamate uptake by examining
how sham and brain-injured animals were able to clear exogenous applications of
glutamate within the striatum. Local application of small volumes of glutamate into the
extracellular space, allowed us to mimic endogenous glutamate release and examine
clearance of glutamate back to baseline values. The primary mechanism for removing
glutamate from the extracellular space is glutamate uptake via EAATs. Diffusion of
glutamate also plays a role in lowering the extracellular glutamate concentration, but is
limited by the extracellular anatomy (Danbolt 2001). Representative recordings
demonstrate slower glutamate clearance after TBI than sham (Fig 3.4A). Since the
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amplitude of the glutamate signals were similar between sham (30.4 ± 1.6 µM) and TBI
(32.4 ± 1.9 µM) [t14 = 0.8139, p = 0.429] (Fig 3.4B), we compared specific parameters of
glutamate clearance (Nickell, et al. 2007, Thomas, et al. 2009, Thomas, et al. 2011).
After local application of glutamate, glutamate levels spike and rapidly returned to
baseline concentrations as glutamate diffused from the local area and through uptake of
glutamate from the extracellular space. We calculated the Trise, the time for the signal to
reach the maximum amplitude, to examine if injury altered diffusion of glutamate in the
extracellular space. The Trise was not significantly altered after TBI (1.8 ± 0.1 s)
compared to sham (1.9 ± 0.1s) [t14 = 1.129, p = 0.278] (Fig 3.4C). Since, no differences
in diffusion were detected after injury, any reductions in glutamate clearance likely result
from decreases in glutamate uptake. TBI produced a significant decrease in k-1, a
measure of glutamate uptake, (0.31 ± 0.05 s-1), compared to sham (0.48 ± 0.07 s-1) [t14 =
2.166, p = 0.048] (Fig 3.4D). Also, TBI produced a significantly longer T80, time for the
signal to decay by 80% from the peak amplitude (4.5 ± 0.6 s), compared to sham (3.2 ±
0.2 s) [t14 = 2.184, p = 0.047] (Fig 3.4E). Thus, TBI produced significant decreases in
glutamate clearance, without altering diffusion rates of extracellular glutamate between
sham and TBI. Functional decreases in glutamate uptake are likely to be a primary
mechanism responsible for increased extracellular glutamate after TBI.

Discussion
The purpose of this study was to examine the regulation of extracellular
glutamate by both neurons and glia to determine the specific mechanism(s) responsible
for the increase in extracellular glutamate in the rat striatum two days after diffuse brain
injury. By combining glutamate-sensitive MEAs with targeted pharmacological agents,
we were able to examine the neuronal and glial contributions to the release and
regulation of extracellular glutamate. In sham animals, presynaptic calcium channeldependent neuronal glutamate release significantly contributed to extracellular
glutamate. Glia were also found to regulate extracellular glutamate as inhibition of
EAATs produced a significant increase in extracellular glutamate. Two days after diffuse
brain injury, we detected significant post-traumatic disruptions in the regulation of
extracellular glutamate by both neurons and glia. In brain-injured animals, the
contribution of presynaptic calcium channel-dependent neuronal glutamate release to
extracellular glutamate was significantly decreased compared to sham. In addition, TBI
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produced increased glutamate spillover from the inhibition of glutamate uptake in the
striatum of brain-injured rats. Furthermore, brain-injured animals exhibited slower
clearance of extracellular glutamate due primarily to decreases in glutamate uptake, yet
not necessarily due to decreases in GLAST and GLT-1 gene expression. These results
are depicted in schematic format to highlight possible sites of dysregulation in the injuryinduced increase in extracellular glutamate (Fig 3.5).
Calcium channel-dependent neuronal glutamate release contributes extracellular
glutamate in sham animals
In sham animals, local application of ω-conotoxin produced a significant ~80%
decrease in extracellular glutamate, suggesting that a majority of extracellular glutamate
measured by MEAs is of a neuronal origin. This result is similar to another study using
MEAs, where local application of ω-conotoxin (mixed channel type) produced a
significant ~50% decrease in the extracellular glutamate concentration in awake freely
moving animals (Hascup, et al. 2010). Collectively, these results confirm that MEAs
measure extracellular glutamate derived, in part, from calcium-dependent neuronal
release. In contrast to the MEA studies, extracellular glutamate sampled by microdialysis
is insensitive to sodium/calcium channel blockers; suggesting the extracellular pool of
glutamate sampled with microdialysis is of a non-neuronal origin (Timmerman and
Westerink 1997). The discrepancy that MEAs detect neuronally derived glutamate,
whereas microdialysis samples extracellular glutamate derived from non-neuronal
origins, may be due to inherent differences in the methodologies. The extensive damage
to the local brain area during implantation of the microdialysis probe and the large area
of tissue sampled (1-4 mm in length), restricts microdialysis measurements of glutamate
to large regions far beyond synapses (Timmerman and Westerink 1997, Obrenovitch
1999, Obrenovitch, et al. 2000, Borland, et al. 2005, Hillered, et al. 2005, Jaquins-Gerstl
and Michael 2009). Furthermore, the inadequate temporal resolution of microdialysis
(~1-20 min) prevents microdialysis from detecting the rapid dynamic changes in
extracellular glutamate that occur in the order of milliseconds to seconds (Diamond
2005). The improved spatial resolution (333 µm in length), limited damage to the local
area from implantation of the device and fast temporal resolution (2 Hz) allow MEAs to
detect the fast dynamics of glutamate closer to synapses and detect extracellular
glutamate that is neuronally derived (Day, et al. 2006, Hascup, et al. 2007, Rutherford, et
al. 2007, Hascup, et al. 2009, Hascup, et al. 2010).
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Reduced calcium channel-dependent neuronal glutamate release in brain-injured
rats
In contrast to sham animals, local application of ω-conotoxin failed to significantly
reduce the extracellular glutamate concentration compared to saline after TBI. This shift
in the source of glutamate release from neuronal sources in sham to non-neuronal
sources after TBI could be explained by two different mechanisms. First, there could be
a post-traumatic decrease in neuronal glutamate release with a concurrent increase in
non-neuronal sources of glutamate. Non-neuronal sources of extracellular glutamate can
include: One, micropores in cellular membranes from the primary injury forces can
release glutamate into the extracellular space due to the higher concentrations of
glutamate found in the cytosol or blood (Schmidt and Grady 1993, Koizumi, et al. 1997).
Two, activated microglia can release glutamate into the extracellular space in response
to inflammatory cytokines after TBI (Brown and Neher 2010). Three, glutamate can be
released from the xc-, which may be enhanced after injury for the production of
glutathione, a major cellular anti-oxidant (Baker, et al. 2002, Domercq, et al. 2007). Four,
EAATs can reverse due to ionic and metabolic disruptions after TBI transporting
glutamate into the extracellular space (Gemba, et al. 1994, Phillis, et al. 2000, Hamann,
et al. 2002). Overall, the observed reduction in presynaptic calcium channel-dependent
vesicular glutamate release after TBI may be a compensatory mechanism for increases
in non-vesicular sources of glutamate.
A second mechanism that may contribute to the decrease in presynaptic calcium
channel-dependent glutamate release after TBI is a post-traumatic alteration in the
mechanism of vesicular glutamate release that is independent of calcium entry through
the N-type calcium channel. Neurons are capable of vesicular release independent of
calcium entry from the extracellular space, as internal calcium stores can mobilize from
the mitochondria and endoplasmic reticulum for vesicular release (Ryglewski, et al.
2007, Neher and Sakaba 2008). After midline FPI, neurons have exhibited disrupted
calcium regulation with increasing intracellular calcium levels (Sun, et al. 2008, McGinn,
et al. 2009). The disrupted internal calcium regulation and a post-traumatic shift utilizing
internal calcium stores for vesicular glutamate release may explain why blocking the Ntype calcium channel with ω-conotoxin failed to reduce extracellular glutamate in braininjured animals.
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Neuronal regulation of extracellular glutamate (mGluR2/3)
Transient activation of the glutamate autoreceptors (mGluR2/3) has been reported
to regulate neuronal glutamate release (Bond, et al. 1999), potentially restoring
extracellular glutamate levels in the injured brain. The mGluR2/3’s are G-protein linked
receptors that negatively regulate adenylate cyclase and decrease levels of cyclic
adenosine monophosphate (Danbolt 2001). The mGluR2/3 act as negatively coupled
autoreceptors providing presynaptic inhibition of glutamate release (Nakanishi 1994, Di
Iorio, et al. 1996, Battaglia, et al. 1997, Allen, et al. 1999, Schoepp 2001). In sham
animals, local application of LY 379268 failed to significantly reduce extracellular
glutamate compared to saline. Whereas, a previous study in awake animals detected a
significant ~20% decrease in the extracellular glutamate from local application of LY
379268 (Hascup, et al. 2010). The discrepancy between our results and the
aforementioned study may be due to confounding effects of anesthesia, as urethane has
been shown to dramatically reduce extracellular glutamate by ~60-80% (Rutherford, et
al. 2007).
We hypothesized that local transient activation of mGluR2/3 would reduce
excessive synaptic glutamate release and lower extracellular glutamate, as we have
previously shown increased amounts of neuronal glutamate release from local
depolarization in the rat striatum two days after TBI (Hinzman, et al. 2010). Furthermore,
multiple reports have shown LY 379268 to be neuroprotective in ischemia and TBI
models (Cai, et al. 1999, Bond, et al. 2000, Stover, et al. 2003, Movsesyan and Faden
2006). However, in brain-injured animals transient local application of LY 379268 failed
to reduce extracellular glutamate compared to saline. The inability of LY 379268 to
reduce extracellular glutamate was also seen in a prior study, where a single i.p.
injection of LY 379268 improved EEG activity, reduced contusion volume, but failed to
reduce extracellular glutamate; suggesting LY 379268 works through other mechanisms
to provide neuroprotection than solely reducing extracellular glutamate (Stover, et al.
2003).

Glial source of extracellular glutamate (xc-)
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We also examined glial glutamate release through the xc-, a potential nonneuronal source of extracellular glutamate, by locally applying xc- blocker (CPG). The xc-,
predominantly localized to glia, is an anti-porter internalizing cystine with simultaneous
release of glutamate; xc- plays a vital role in the prevention of oxidative damage by
importing cystine for the production of glutathione, a major anti-oxidant in the cell
(Albrecht, et al. 2010). The xc- has been proposed as a major source of extracellular
glutamate with CPG producing a significant ~60% decrease in extracellular glutamate
sampled by microdialysis (Baker, et al. 2002). In our study, local application of CPG
failed to significantly reduce extracellular glutamate compared to saline in both sham
and TBI animals. Similar to our data, multiple reports have detected no significant
change in extracellular glutamate with application of CPG in both anesthetized and
awake animals (Melendez, et al. 2005, Hascup, et al. 2010, Lupinsky, et al. 2010). In
general, the data reported here and from prior reports suggest a limited role for the xc- as
a source of extracellular glutamate.

Glutamate uptake through EAATs regulates extracellular glutamate
In sham animals, we examined the role of EAATs on regulating extracellular
glutamate by locally applying the EAAT competitive blocker, TBOA. Local application of
TBOA into the extracellular space produced a robust increase in the extracellular
glutamate concentration as TBOA inhibited glutamate uptake by the EAATs allowing
more glutamate to escape from the synapses. Prior studies, using both microdialysis and
MEAs have detected similar increases in the extracellular concentration of glutamate
with inhibition of EAATs which equates to increases in extracellular glutamate ranging
from ~125-800% (Montiel, et al. 2005, Day, et al. 2006, Tovar, et al. 2009, Hascup, et al.
2010). Collectively, our data and the previous reports support the importance of EAATs
in regulating extracellular glutamate.

Increased glutamate spillover from the inhibition of glutamate uptake in braininjured rats
Similar to sham animals, in brain-injured animals local application of TBOA into
the extracellular space produced a robust increase in extracellular glutamate. In addition,
TBI resulted in a significantly greater increase in the amount of glutamate spillover from
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the synapses of brain-injured animals compared to sham. The increase in glutamate
spillover when challenged with an uptake inhibitor suggests either a post-traumatic
decrease in EAATs expression or function. Although we did not detect a significant
decrease in the expression of GLAST and GLT-1 genes; multiple reports have detected
post-traumatic reductions in the expression of EAATs in both the clinic and experimental
models of TBI (Rao, et al. 1998, van Landeghem, et al. 2001, Yi, et al. 2005, van
Landeghem, et al. 2006, Yi and Hazell 2006).

Decreased glutamate clearance in brain-injured rats
Rapid application of glutamate into the extracellular space allowed us to mimic
endogenous glutamate release events and examine the ability of EAATs to take up
glutamate in vivo. Here, we report significant decreases in glutamate clearance after
TBI. The post-traumatic decrease in glutamate clearance seems to be due to decreases
in glutamate uptake and not due to alterations in the diffusion of glutamate within the
extracellular space. If TBI drastically altered the tortuosity of the extracellular space, we
would expect a post-traumatic change in the diffusion of glutamate in the extracellular
space (Nicholson, et al. 2000). However, we detected no significant change in the Trise
as glutamate diffused from the point source (micropipette) to the MEA, suggesting the
decreased glutamate clearance is due to decreased glutamate uptake. Post-traumatic
reductions in glutamate uptake can play a pivotal role in the pathophysiology of TBI over
stimulating metabotropic and ionotropic glutamate receptors. Peri-contusional tissue
exhibits decreased expression of EAATs in both the clinic and experimental models of
TBI (Rao, et al. 1998, van Landeghem, et al. 2001, Yi, et al. 2005, van Landeghem, et
al. 2006, Yi and Hazell 2006). Furthermore, knockdown expression of GLAST and GLT1 produces increased neuronal damage in an experimental model of TBI (Rao, et al.
2001). These studies demonstrate the importance of maintaining proper glutamate
uptake to prevent the initiation and propagation of secondary injury cascades and
development of a contusion. Early post-traumatic disruptions in glutamate clearance
may play a role in the development of late-onset gain-of function behavioral morbidity
that is correlated with changes in glutamate hypersensitivity (Thomas, et al. 2011).
Although we do not know if the disruptions in the regulation of extracellular glutamate will
hold true for later time points or indefinitely, prior work has detected persistent changes
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in glutamate excitability in the thalamus and somatosensory cortex (Thomas, et al.
2011).
Decreased glutamate uptake is likely the primary mechanism for increased
extracellular glutamate after injury. With reduced glutamate uptake, more glutamate can
spill out from the synapse increasing extracellular glutamate over time. Furthermore,
reduced glutamate uptake is likely responsible for the increased KCl-evoked glutamate
release seen in our prior study (Hinzman, et al. 2010). A decrease in glutamate uptake
would allow more glutamate to escape from the synapse, producing larger amplitudes
during evoked release. Previously, we did not detect any post-traumatic decrease in
glutamate clearance parameters from KCl-evoked glutamate release most likely due to
the disruptions in the electrochemical gradient required for depolarization, which is
circumvented by local application of glutamate itself.

Conclusion
Using MEAs and targeted pharmacological agents, we were able to examine how
neurons and glia release and regulate extracellular glutamate in vivo. Two days after
diffuse brain injury the contribution of calcium-mediated glutamate release via the N-type
calcium channel was significantly reduced. Also, TBI produced a significant decrease in
glutamate clearance that was primarily due to decreases in glutamate uptake. Future
work should examine if enhancing expression of the EAATs, either by viral mediated
expression or stimulating expression through the use of beta-lactam antibiotics
(Rothstein, et al. 2005, Harvey, et al. 2011), produces an overall improvement in
glutamate regulation and behavioral outcomes in experimental models of TBI. In
addition, drugs that can improve the function and/or surface expression of EAATs
remain possible therapeutic targets to improve outcomes following TBI.

Chapter Three has been published in the following manuscript:
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Figure 3.1 Increased extracellular glutamate in the striatum of brain-injured rats at
two days after midline fluid percussion brain injury
Higher levels of extracellular glutamate in the straitum of brain-injured rats compared to
sham, (n =16, * p < 0.05).
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Figure 3.2 Reduced calcium channel-dependent glutamate release in the striatum
of brain-injured rats
(A) Baseline-matched traces of extracellular glutamate demonstrate the average effect
of 100 nL local application (↑) of 10 µM ω-conotoxin, N-type calcium channel blocker, on
extracellular glutamate in sham (blue) and TBI animals (red). (B) The maximum
decrease in extracellular glutamate from local application of ω-conotoxin was
significantly smaller after TBI than sham. (C) The extent of reduced extracellular
glutamate with respect to time (area under curve) was significantly reduced after TBI
than sham (n = 4, * p < 0.05).
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Figure 3.3 Increased glutamate spillover from inhibition of glutamate uptake in the
striatum of brain-injured rats
(A) Traces of extracellular glutamate showing the average response from 100 nL local
application (↑) of 100 µM TBOA, excitato ry amino acid transporter blocker, in sham
(blue) and TBI (red). (B) The maximum increase in extracellular glutamate from local
application of TBOA was significantly elevated after TBI compared to sham. (C) The
extent of higher extracellular glutamate with respect to time (area under curve) was
significantly increased after TBI than sham (n = 4, * p < 0.05).
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Figure 3.4 Decreased glutamate clearance in the striatum of brain-injured rats
(A) Representative glutamate signals in the striatum from local application of 500 µM
glutamate (↑) in sham (blue ) and TBI (red) showed significant decreases in glutamate
uptake parameters after TBI. (B) The amplitude of the glutamate signal was similar
between sham and TBI groups. (C) Trise, an indicator of glutamate diffusion, was similar
between sham and TBI groups. (D) k-1, an indicator of glutamate uptake rate, was
significantly reduced after TBI compared to sham. (E) T80, an indicator of glutamate
clearance, was significantly longer after TBI compared to sham (n = 8, * p < 0.05).
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Figure 3.5 Schematic depicting the regulation of extracellular glutamate in the rat
striatum in sham and brain-injured animals
In sham animals, neurons release glutamate into the extracellular space that is
dependent on calcium entry through N-type calcium channels. Once in the extracellular
space, glutamate acts on both metabotropic and ionotropic glutamate receptors for
signal propagation. Glutamate is removed from the extracellular space by excitatory
amino acid transporters, predominantly localized to glia. Glutamate uptake is the primary
mechanism for removal of extracellular glutamate and is responsible for regulating the
concentration extracellular glutamate. After TBI, we detected post-traumatic disruptions
in the regulation of extracellular glutamate by both neurons and glia. In brain-injured
animals, calcium-dependent glutamate release via N-type calcium channels was no
longer a source of extracellular glutamate. Also, the uptake of glutamate by excitatory
amino acid transporters was reduced in brain-injured animals. Post-traumatic decreases
in glutamate uptake is likely the primary mechanism responsible for increased
extracellular glutamate after TBI.
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Chapter Three: Tables

Table 3.1 Effect of local application of drugs on extracellular glutamate in sham
and traumatic brain injured (TBI) animals

Local
Application

Maximum Change From
Baseline Glutamate (µM)

Area Under Curve
(AU)

Sham

TBI

Sham

TBI

saline

-0.7 ± 0.2

-0.4 ± 0.1

40.7 ± 21.1

11.6 ± 5.1

ω-conotoxin

-2.6 ± 0.8*

-0.4 ± 0.1

343.8 ± 97.8*

33.7 ± 18.6

saline

0.4 ± 0.4

1.0 ± 0.1

2.4 ± 2.1

2.3 ± 2.3

TBOA

5.2 ± 1.7*

8.5 ± 0.8*

26.3 ± 5.3*

53.6 ± 9.4*

Mean ± SEM; * p <0.05 (treatment vs. saline); n=4
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Preface to Chapter Four
In the previous chapters I have demonstrated disruptions in the regulation of
extracellular glutamate after diffuse brain injury. The aim of the experiments in Chapter
Four was to examine a novel approach to improve the regulation of extracellular
glutamate. Using a viral vector-mediated gene delivery approach, we examined if
infusion of adeno-associated virus expressing glutamate transporter-1 (AAV-GLT-1)
could produce targeted expression of functional GLT-1 and improve the regulation of
extracellular glutamate in the rat striatum.

Chapter Four: Targeted expression of the glutamate transporter, GLT-1, in
the rat striatum using a viral vector-mediated gene delivery approach

Abstract
Glutamate neurotransmission is involved in almost all aspects of neurological
function. Dysregulated glutamate signaling has been implicated in a host of
neurodegenerative and neuropsychiatric disorders. Increases in extracellular glutamate
can excessively activate glutamate receptors producing excitotoxicity. To prevent
excitotoxic accumulation of extracellular glutamate, the central nervous system has
developed an abundant system of glutamate transporters to regulate extracellular
glutamate. The purpose of this study was to examine if a viral vector-mediated gene
delivery approach, adeno-associated virus (AAV), could target the expression of
functional glutamate transporter (GLT-1) in the rat striatum. To examine the expression
of functional GLT-1, glutamate-sensitive microelectrode arrays (MEAs) were used to
measure clearance kinetics of locally applied glutamate into the extracellular space in
rats infused with either AAV-GLT-1 or AAV-GFP (green fluorescent protein).

Three

weeks after viral infusion, the clearance of glutamate was significantly faster in the
striatal hemisphere infused with AAV-GLT-1/RFP (red fluorescent protein) than the
hemisphere infused with AAV-GFP. Thus, using a viral vector-mediated gene delivery
approach, we were able to increase glutamate clearance, indicating increased
expression of functional GLT-1. Overall, these data suggest a novel therapeutic strategy
to improve glutamate uptake, which may improve glutamate regulation and reduce
excitotoxicity.
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Introduction
Glutamate, the predominant excitatory neurotransmitter in the central nervous
system, is involved in almost all aspects of neurological function including cognition,
motor function, memory, learning, decision making, and neuronal plasticity (McEntee
and Crook 1993, Danbolt 2001). For normal neurological function, glutamate signaling
must be properly regulated. Glutamate is released into the extracellular space where
glutamate binds to both metabotropic and ionotropic glutamate receptors for propagation
of the excitatory signal (Jabaudon, et al. 1999, Jensen, et al. 2000). Appropriate
activation of glutamate receptors requires tight regulation of the extracellular
concentration of glutamate. Concentrations of extracellular glutamate are maintained low
by the uptake of glutamate via five high affinity sodium-dependent excitatory amino acid
transporters (EAATs), GLAST, GLT-1, EAAC, EAAT4, and EAAT5 (Danbolt 2001). A
majority (~90%) of glutamate uptake is performed by two glial transporters in the rat
forebrain, GLAST and GLT-1 (Rothstein, et al. 1996, Tanaka, et al. 1997, Danbolt 2001).
Dysregulated glutamate signaling has been implicated in a host of neurological
and neuropsychiatric disorders including TBI, stroke, Parkinson’s disease, Alzheimer’s
disease, Huntington’s disease, amyotrophic lateral sclerosis, epilepsy, schizophrenia,
drug addiction, anxiety and depression (Doble 1999, Danbolt 2001, Nanitsos, et al.
2005, Mathew, et al. 2008, McNally, et al. 2008). Disruptions in the regulation of
extracellular glutamate can produce increases in extracellular glutamate excessively
activating glutamate receptors. Excessive stimulation of glutamate receptors can induce
“excitotoxicity”,

a

neuropathological

processes

involving

prolonged

neuronal

depolarization, increases in intracellular calcium concentration, and activation of
enzymatic mechanisms of cell death (Olney and de Gubareff 1978, Faden, et al. 1989,
Doble 1999, Doyle, et al. 2008). Excitotoxicity is thought to be one of the predominant
pathophysiological processes involved in neuronal damage and death in traumatic brain
injury and stroke as excitotoxic concentrations of glutamate have beed detected in
stroke and TBI survivors (Bullock, et al. 1995, Davalos, et al. 2000).
Inhibiting excitotoxicity through the use of glutamate receptor antagonists has
been a therapeutic strategy for the treatment of stroke and traumatic brain injury for
many years (Willis, et al. 2004, Muir 2006, Garber 2007). Multiple studies have reported
reduced damage and improved outcomes with the use of glutamate receptor antagonist
in experimental models of stroke and traumatic brain injury (Simon, et al. 1984,
Sheardown, et al. 1990, Myseros and Bullock 1995, Shen, et al. 2005, Shen, et al.
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2009). However, glutamate receptor antagonists have failed to translate into positive
clinical outcomes due to a lack of efficacy and/or adverse effects in the central nervous
system (Bullock 1995, Ikonomidou and Turski 2002, Hoyte, et al. 2004, Villmann and
Becker 2007). Taken together, these results support the examination of alternate
strategies to improve the regulation of extracellular glutamate, which may produce the
same beneficial effects while limiting the adverse effects observed with glutamate
receptor antagonist.
Intraperitoneal administration of a beta-lactam antibiotic, ceftriaxone, has been
shown to increase the expression of glutamate transporters in the rat brain, and reduce
neuronal damage and improve behavioral recovery in a rat model of stroke (Rothstein,
et al. 2005, Chu, et al. 2006, Chu, et al. 2007). These results suggest strategies that
increase functional glutamate transporter levels can improve the regulation of
extracellular glutamate and limit excitotoxicity. The purpose of this study was to examine
if a novel approach, viral vector-mediated gene delivery of GLT-1 using an adenoassociated virus (AAV), could target the expression of functional GLT-1 in the rat
striatum. Furthermore, we examined two different strategies of infusing the viral-vectors
to determine which infusion method produced the optimal distribution and expression of
GLT-1. In the first study, we examined whether a single infusion of AAV-GLT-1/RFP,
expressing both the glutamate transporter and red fluorescent protein, would express
functional GLT-1 in the rat striatum. In the second study, we examined whether infusing
AAV-GLT-1 in multiple locations within the striatum would enhance the expression and
distribution of functional GLT-1. To examine the expression of functional GLT-1,
glutamate-sensitive microelectrode arrays (MEAs) measured the clearance of glutamate
locally applied into the extracellular space three weeks after infusions.

Materials and Methods

Animals
In the first study, male Fischer 344 rats (n=3, Harlan Laboratories Inc., IN) were
used, weighing 250-350 g at the time of infusion. In the second study, male SpragueDawley rats (n= 12, Harlan Laboratories Inc.) were used, weighing 250-350 g at the time
of infusion. The animals were housed in a 12 h light/dark cycle with food and water
available ad libitum and handled in accordance with guidelines from the Guide for the
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Care and Use of Laboratory Animals (7th edition) and to the Association for Assessment
and Accreditation of Laboratory Animal Care International. Animals were acclimated to
their environment for at least one week before any experiments. After infusion, animals
were monitored daily for post-operative care. Animal care was approved by the
University of Kentucky Institutional Animal Care and Use Committee.

Construction, packaging, purification and titering of AAV vectors
The rat complimentary DNA (cDNA) for GLT-1 was first polymerase chain
reaction (PCR) amplified from pc-GLT-1(Pines, et al. 1992) (from Dr. Mike Robinson at
U. Pennsylvania). The amplified PCR product contained BamHI (5’ end) and XbaI (3’
end) restriction enzyme sites used to insert the PCR product into pCR8/GW/TOPO
(Invitrogen, CA) as an intermediate. The BamHI/Xba1 fragment replaced GFP in the
BamHI/XbaI digestion of pssAAV-GFP (Lowery, et al. 2009) to create pssAAV-GLT1.
Viral stocks of AAV-GLT1 serotype 1 were prepared using the triple-transfection method
(Xiao, et al. 1998, Howard, et al. 2008, Lowery, et al. 2009). Virus was provided by Dr.
Brandon Harvery, National Institute on Drug Abuse (NIDA).

Intracerebral AAV injections
Rats were anesthetized with 3% isoflurane, and placed in a stereotaxic frame
(Kopf Instruments, Tujunga, CA). Animal body temperature was maintained at 37°C with
a heating pad (Braintree Scientific, Braintree, MA) and the animals’ eyes were lubricated
with artificial tears (The Butler Company, OH). The skin directly on top of the animal’s
head was cleaned with a betadine solution. Then a small incision was made over the
skull to reflect the skin. Burr holes were drilled into the skull to provide access for the
infusion of the virus. Before loading the syringe, the virus was sonicated for 10 s, and
then loaded into a Hamilton syringe (33 gauge) (Hamiltion Company, NV). The needle
was stereotaxically placed into the area of interest with a two minute waiting period
before starting the infusion. Virus was infused at a flow rate of 0.5 µl/min using an
injection pump (UMP2; World Precision Instruments, FL) with a two minute waiting
period before removal of the syringe. The burr holes were sealed with bone wax and
skin sutured. Surgeries were performed with assistance from Dr. Brandon Harvey, NIDA.

63

For the single infusion, burr holes were drilled bilaterally for infusion of the virus into the
striatum (AP: +1.0, ML: +/- 2.5, DV: -4.5). Each hemisphere received either 3 µl of AAVGFP or AAV-GLT-1/RFP (Fig 4.1).
For the multiple infusions, burr holes were drilled bilaterally to provide access for
infusion of the virus into the striatum, and 2 µl of virus was infused into four locations in
each hemisphere (AP: +0.5, ML: 2.0 and 3.5, DV: -4.0 and -5.0). Each hemisphere
received a total of 8 µl of AAV-GFP or AAV-GLT-1 (Fig 4.2).

Enzyme-based microelectrode arrays
Ceramic-based microelectrode arrays (MEAs) consisting of four platinum
recording sites (15 x 333 µm) arranged in dual pairs were prepared and selected for in
vivo recordings as previously described, (Burmeister, et al. 2002, Day, et al. 2006,
Hascup, et al. 2007, Stephens, et al. 2009, Hinzman, et al. 2010, Hinzman, et al. 2012).
Two different coatings were applied to the MEAs. One pair of recording sites was coated
with glutamate-oxidase to allow for the enzymatic conversion of glutamate to αketoglutarate and the reporter molecule H2O2. Constant potential amperometry was
performed at a potential + 0.7 V versus a silver/silver chloride reference to oxidize H2O2
yielding two electrons. The resulting current was amplified and digitized by the FAST-16
mkII system (Fast Analytical Sensor Technology Mark II; Quanteon, L.L.C., KY). The
other pair of recording sites (Sentinel sites) was coated with an insensitive protein matrix
of bovine serum albumin and glutaraldehyde to measure any background current. The
application of two different coatings allowed the use of a self-referencing technique,
where the current from sentinel sites could be subtracted from the current from the
glutamate-oxidase sites thus producing a more selective glutamate measure. A size
exclusion layer of 1,3-phenylenediamine (mPD) was electroplated to the platinum
recording sites blocking interferents such as ascorbic acid (AA) and dopamine (DA) from
reaching the platinum recording sites (Hinzman, et al. 2010, Thomas, et al. 2011,
Hinzman, et al. 2012).

MEA/micropipette assembly
For local application of glutamate into the rat brain, glass micropipettes (1 mm
o.d. 0.58 mm i.d., A-M Systems, Inc., WA) were pulled (Kopf Instruments, CA), and the
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tips of the micropipettes were bumped to create a tip with an i.d. of 10-15 µm. The
micropipettes were placed centrally among all four platinum recording sites and mounted
50-100 µm above the MEA. Micropipettes were filled with 500 µM or 1 mM glutamate
(Sigma-Aldrich, MO), dissolved in physiological saline. Solutions were sterile filtered
(0.20 µm) and adjusted to a pH of 7.4. The micropipette was connected to a Picospritzer
III (Parker-Hannifin, OH) with settings adjusted to consistently deliver volumes between
12.5-350 nL. Pressure was applied from 2-30 psi for 0.3-1.0 sec. Volume displacement
was monitored with the use of a stereomicroscope fitted with a reticule to determine and
control the volume of solution that was locally applied by pressure ejection (Friedemann
and Gerhardt 1992).

In vivo anesthetized recordings of extracellular glutamate
Three weeks after viral infusion, rats were anesthetized with urethane (1.25 g/kg
i.p.) and prepared for in vivo electrochemical recordings as previously described (Day, et
al. 2006, Hascup, et al. 2007, Stephens, et al. 2009, Thomas, et al. 2009, Hinzman, et
al. 2010, Thomas, et al. 2011, Hinzman, et al. 2012). Briefly, MEAs were calibrated the
morning of the experiment and the calibration values (sensitivity, selectivity, and limit of
detection) were comparable to previous studies.

Then, animals were placed in a

stereotaxic frame and body temperature was maintained at ~37 °C with a water pad
connected to a recirculating water bath. A craniotomy was performed to provide access
to the striatum. A Ag/AgCl reference wire was implanted into the lateral parietal cortex.
The MEA was lowered into the striatum using a microdrive (MO-10, Narishige
International, NY). All MEA recordings were performed at a frequency of 2 Hz.
Glutamate recordings were performed in both hemispheres comparing the AAV-GLT-1
treated hemisphere to the AAV-GFP treated hemisphere. To examine glutamate
clearance, varying volumes of 500 µM or 1 mM glutamate were applied into the
extracellular space producing glutamate signals with amplitudes in the 5-200 μM range.
Glutamate clearance was analyzed by the following parameters: (1) amplitude (μM); (2)
T80 (s), the time for the signal to decay by 80% from the peak amplitude; (3) uptake rate
constant k-1 (sec -1), the slope of the linear regression of the natural log transformation of
the decay over time; and (4) clearance rate Tc (μM/sec) the slope of the line between T20
and T60 (Nickell, et al. 2007, Thomas, et al. 2009, Hinzman, et al. 2010) (Fig 4.3).
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In the first study, clearance of locally applied glutamate was examined 0.1 mm
lateral to the infusion site of the virus (AP: +1.0, ML: ± 2.6, DV: -4.5), represented by *
(Fig 4.1). In the second study, clearance of locally applied glutamate was examined in
between the two infusion tracks at multiple depths in the striatum (AP: +0.5, ML: ± 3.3,
DV: -4.0, -4.5 and -5.0), represented by *(Fig 4.2).

Data analysis
Amperometric data were analyzed using custom MATLAB® - based software.
Data are presented as mean ± SEM, and statistical significance was defined as p < 0.05.
A two-tailed t-test was used for comparisons between the AAV-GFP and AAV-GLT-1
treated hemisphere, unless noted otherwise.

Histology
In the first study, after completion of the glutamate recordings, animals were
transcardially perfused with physiological saline followed by 4% paraformaldehyde.
Brains were removed and stored in 4% paraformaldehyde for 3 days. At the end of the 3
days, the storage solution was exchanged to 0.1m phosphate buffer with 30% sucrose.
Brains were sliced on a cryostat (0.05 mm) for visualization of GFP or RFP fluorescence.
Histology was performed in Dr. Brandon Harvey’s Laboratory, NIDA.

Quantitative gene expression (rtPCR)
In the second study, after completion of the glutamate recordings, animals were
transcardially perfused with cold saline, the brains rapidly removed from the skull,
dissected into 2 mm slices using a chilled rat brain matrix, and a 2 mm diameter biopsy
was removed from the dorsal striatum, approximate area represented in (Fig 4.2). The
mRNA content was stabilized (RNAlater, Qiagen Corp) and stored frozen (-20◦C).
Isolated mRNA (RNeasy, Qiagen Corp) was quantified (NanoDrop ND-1000
spectrophotometer), converted to cDNA (High Capacity cDNA Archive Kit, Applied
Biosystems Inc.) and then used as a template for selected commercially-available gene
expression assays for quantitative real-time PCR (StepONE, Applied Biosystems). The
Applied Biosystems TaqMan® Gene Expression Assays (GLT-1: Rn00568080_m1) were

66

used for GLT-1 gene expression. Within each animal, relative gene expression was
normalized to the 18s rRNA endogenous control and the expression level in the AAVGFP hemisphere using the 2-ΔΔCT method (Livak and Schmittgen 2001), which relates
gene expression to the PCR cycle number at which the fluorescence signals exceed a
threshold above baseline. Relative gene expression was compared between AAV-GFP
and AAV-GLT-1 striatal punches using a two-tailed t-test.

Results

Single infusion of AAV- GLT-1/RFP increases expression of functional GLT1 in the rat striatum
Three weeks after a single infusion of AAV-GFP or AAV-GLT-1/RFP into the rat
striatum, we examined if viral-mediated expression could produce an increase in
functional GLT-1. Using glutamate-sensitive MEAs we examined glutamate clearance
0.1 mm lateral to the infusion site comparing the AAV-GLT-1/RFP treated hemisphere to
the AAV-GFP treated hemisphere. Local application of varying amounts of 1 mM
glutamate produced reproducible glutamate signals with amplitudes ranging from 50-200
µM. Local application of glutamate produced a rapid increase in extracellular glutamate,
with the signal reaching the maximum amplitude in less than 2 seconds, followed by a
decrease in the signal as glutamate uptake restored the glutamate concentration back to
baseline levels (Fig 4.3). Glutamate signals with similar amplitudes were used to
compare glutamate clearance between the AAV-GFP treated hemisphere to the AAVGLT-1 treated hemisphere. Due to the small number of animals used in this study (n=3),
we were only able to obtain glutamate signals with similar amplitudes in a limited range.
Representative glutamate signals, in the 170-185 µM amplitude range, highlight the
faster glutamate clearance rate Tc (the slope of the line between T20 and T60) in the AAVGLT-1/RFP striatal hemisphere compared to the AAV-GFP treated hemisphere (Fig
4.4A). Tc was compared between AAV-GLT-1/RFP and AAV-GFP treated striatal
hemispheres based on the amplitude of the glutamate signal. Tc was significantly
affected by the viral treatment ANOVA [F(1,16)=31.97, p<0.0001]. The AAV-GLT-1/RFP
treatment produced significantly faster glutamate clearance rates than AAV-GFP
treatment in the 150-165 µM (134%) and 170-185 µM (126%) amplitude ranges
(Bonferroni post-test, * p< 0.05, ** p< 0.01, Fig 4.4B).
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At the conclusion of the experiment, the brains were sectioned to visually confirm
expression and distribution of the fluorescent proteins. In a coronal section of the rat
striatum, we were able to confirm that infusion of AAV-GLT-1/RFP and AAV-GFP
produced expression of both red and green fluorescent proteins in their respective
hemispheres (Fig 4.5A). At higher magnification, we were able to visualize the
expression of GFP and RFP in both cellular bodies and elongated processes (Fig 4.5B
and C). Thus, using a viral vector-mediated gene delivery approach, we were able to
increase the expression of functional GLT-1 into the rat striatum.

Multiple infusions of AAV- GLT-1 within the striatum failed to express
functional GLT-1
Three weeks after multiple infusions of AAV-GLT-1 within the rat striatum, we
examined if infusing the virus in multiple locations within the striatum would enhance the
viral-mediated expression and distribution of functional GLT-1 (Fig 4.2). Glutamatesensitive MEAs were used to examine the clearance of exogenously applied glutamate
into the extracellular space in multiple depths of the striatum comparing the AAV-GLT-1
treated hemisphere to the AAV-GFP treated hemisphere. Representative glutamate
signals depict a similar decay of the glutamate signal from exogenous application of
glutamate between the AAV-GFP and AAV-GLT-1 treated hemispheres (Fig 4.6).
Glutamate signals were sorted based on the amplitude of the signals, (<50, 50-100,
>100 µM), and parameters of glutamate clearance were compared between the AAVGFP and AAV-GLT-1 treated hemispheres. Due to the increased number of animals in
this study (n=12) we were able to obtain glutamate signals with a larger range of
amplitudes for comparison. In all the amplitude ranges, we detected no significant
difference in any of the clearance parameters between the AAV-GFP and AAV-GLT-1
treated hemispheres (Table 4.1). These data indicate that multiple infusion loci did not
produce changes in glutamate clearance that would have been indicative of enhanced
functional GLT-1 levels.
At the conclusion of the experiment, we used quantitative real-time PCR to
examine the gene expression of GLT-1. In the dorsal striatum, there was no significant
difference in the relative expression of GLT-1 between the AAV-GFP (0.98 ± 0.2) and
AAV-GLT-1 (1.0 ± 0.1) treated hemispheres (Fig 4.7). Thus, rt-PCR results support the
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conclusion that multiple injections of AAV-GLT-1 into the striatum failed to increase gene
expression of GLT-1.

Discussion
The purpose of this study was to examine if a viral vector-mediated gene delivery
approach (AAV-GLT-1) could target the expression of functional GLT-1 into the rat
striatum and thereby improve the regulation of extracellular glutamate. In the single
infusion study, infusion of AAV-GLT-1/RFP into the striatum produced significantly faster
glutamate clearance compared to infusion of AAV-GFP. We were able to confirm
expression of the fluorescent protein tags RFP and GFP in their respective striatal
hemisphere with expression of both proteins in cell bodies and elongated processes. In
the multiple infusion study, we tried to enhance the expression and distribution of GLT-1
by infusing AAV-GLT-1 into multiple locations within the striatum. Three weeks after
infusion, we detected no significant difference in glutamate clearance or in the gene
expression of GLT-1 between the AAV-GLT-1 and AAV-GFP treated hemispheres.
Thus, using a viral vector-mediated gene delivery approach, with a single infusion of
AAV-GLT-1/RFP, we were able to increase the expression of functional GLT-1 into the
rat striatum.
We have yet to identify the exact reason why multiple infusions of AAV-GLT-1
failed to produce expression of functional GLT-1, while a single infusion of AAV-GLT1/RFP produced functional expression of GLT-1 in the rat striatum. In the multiple
infusion study, we used two infusion tracks to inject the virus into four separate locations
within the striatum. Multiple insertions of the infusion needle may have produced an
increased amount of damage and inflammation preventing transduction of the virus into
the cells. However, previous work by our collaborator (Dr. Brandon Harvey), achieved
viral-mediated expression of GLT-1 using a multiple infusion design within the rat cortex
(Harvey, et al. 2011). Another possible reason for the lack of expression in the multiple
infusion study is due to differences in the viral vectors. In the single infusion study we
used AAV-GLT-1/RFP while in the multiple infusion study we used AAV-GLT-1,
differences in the construction of the viral-vectors may have produced variances in the
titers and/or transduction efficiency between the viral-vectors. The most likely reason for
lack of expression in the multiple infusion study is a loss of viral integrity due to problems
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in shipping and/or preparing the AAV-GLT-1 for infusion into the striatum. In the future,
improvements in the experimental design need to include transducing primary neuron
cultures using the same aliquot of virus, confirming viral integrity. Also, examining both
histology for fluorescent markers and gene expression will aide in detecting problems
with infusion of the virus.
In both studies, AAV sereotype 1 was used, which has been shown to transduce
both neurons and glia (unpublished observation, Dr. Brandon Harvey). Normally GLT-1
is only expressed on glia, so one of the overall goals of the second study was to
examine how increased expression of GLT-1 in both neurons and glia would alter
multiple aspects of glutamate signaling including glutamate clearance, tonic glutamate,
and KCl-evoked glutamate release (Danbolt 2001). Since we were unable to increase
the gene expression of GLT-1 in the second study, future work should address how
neuronal expression of GLT-1 alters glutamate signaling and regulation.
The overall objective of this study was to identify a novel therapeutic strategy to
improve the regulation of extracellular glutamate that may limit or reduce excitotoxicity.
Recent work by our collaborator (Dr. Brandon Harvey, NIDA) has shown this approach
(AAV-GLT-1) can enhance glutamate regulation, reduce damage, and improve
outcomes in a rat model of stroke. Intracerebral infusions of AAV-GLT-1 into three
cortical sites in the distribution of the right middle cerebral artery prior to occlusion,
reduced cerebral infarction, improved functional recovery, reduced ischemia-induced
glutamate overflow, and reduced tissue damage (Harvey, et al. 2011). The above study
validates the theory that increasing expression of glutamate transporters can improve
glutamate regulation, reduce excitotoxicity, and improve outcomes in a model of
excitotoxicity.
A major advantage of using a viral vector-mediated gene delivery approach is the
ability to target the expression of the glutamate transporter into the brain region of
interest. Targeting the expression only in the area of interest should not alter glutamate
signaling in other brain regions, thereby, limiting adverse effects seen with glutamatereceptor antagonist such as hallucinations, catatonia, ataxia, nightmares, and memory
deficits (Blanke and VanDongen 2009). To date, a viral-vector mediated approach is the
only known method that allows targeting the expression of a glutamate transporter into
the brain region of interest. While administration of ceftriaxone may increase glutamate
transporters, the increase will not be localized to a certain brain region, this may disrupt
glutamate signaling in undesired brain regions producing adverse effects similar to those
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observed with glutamate-receptor antagonist. Future work should thoroughly exam
potential side effects from targeted over-expression of GLT-1. However, a recent study
detected no significant changes in locomotor activity after multiple infusion of AAV-GLT1 in the rat cortex (Harvey, et al. 2011).
A major disadvantage of using a viral vector-mediated gene delivery approach is
the approximate three weeks needed for stable expression of the protein. In our studies,
AAV-GLT-1 was infused three weeks prior to testing to allow for stable expression. The
other

known

method

to

increase

the

expression

of

glutamate

transporters,

intraperitoneal injection of ceftriaxone, takes approximately five days of daily
administration (Rothstein, et al. 2005). The relatively long period amount of time needed
for stable expression of the glutamate transporters by both methods severely inhibits
their potential as a viable treatment to reduce the acute excitotoxicty in stroke and TBI,
which occurs within the first few days (Bullock, et al. 1995, Davalos, et al. 2000). Another
disadvantage of using a viral-vector approach to increase expression of GLT-1 is the
inability to modulate or stop expression after infusion, especially if unwanted side effects
started to occur.
In conclusion, we have used a viral-vector mediated gene delivery approach to
target the expression of functional GLT-1 into the rat striatum. Recent data supports
improving glutamate regulation in pathologies where glutamate is elevated through the
upregulation of glutamate transporters can protect against excitotoxicity and improve
behavioral outcomes in animal models of stroke (Rothstein, et al. 2005, Chu, et al. 2006,
Chu, et al. 2007, Harvey, et al. 2011). Further development of selective gene delivery
may make the use of GLT-1 a more viable therapeutic strategy to treat neurological and
neuropsychiatric disorders involving chronic dysregulation of extracellular glutamate in
discrete brain areas. Future work is needed to identify strategies that rapidly increase
the expression of glutamate transporters as this appears to be a promising therapeutic
strategy to limit acute excitotoxicity and improve outcomes in traumatic brain injury and
stroke survivors.
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Gerhardt G, Hoffer BJ, Wang Y. Targeted over-expression of glutamate transporter 1
(GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS One.
2011;6(8):e22135. Epub 2011 Aug 10.
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Chapter Four: Figures

Figure 4.1 Representation of the sites for the viral infusion and glutamate
recordings in the rat striatum
The diagram shows the approximate location of the viral infusion sites for AAV-GFP
(green circle) and AAV-GLT-1/RFP (red circle) and the approximate location of the
glutamate recording in the rat striatum (*). Bilateral recordings were conducted for
glutamate

clearance

comparing

the

AAV-GFP

hemispheres.
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and

AAV-GLT-1/RFP

treated

Figure 4.2 Representation of the sites for the viral infusion, glutamate recordings,
and tissue punches for gene expression in the rat striatum
The diagram shows the approximate location of the viral infusion sites for AAV-GFP
(green circle) and AAV-GLT-1 (red circle) and the approximate location of the glutamate
recording sites in the rat striatum (*). Bilateral recordings were conducted for glutamate
clearance in multiple depths of the striatum comparing the AAV-GFP and AAV-GLT1/RFP treated hemispheres. Striatal tissue punches (grey circle) were taken to examine
gene expression for GLT-1 using quantitative real-time PCR.
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Figure 4.3 Representative in vivo recording from a glutamate-oxidase site and
sentinel site of the MEA
Local application of various volumes of glutamate into the extracellular space (↑)
produced signals with a wide range of amplitudes. For each signal glutamate clearance
was analyzed using the following parameters: amplitude, k-1, T80, and Tc. Parameters are
shown separately for clarity.
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Figure 4.4 Faster glutamate clearance in AAV-GLT-1 treated hemisphere compared
to AAV-GFP hemisphere
(A) Graph comparing the time course of glutamate clearance from signals with similar
amplitudes in the 170-185 µM range. The GLT-1/RFP-treated hemisphere showed a
faster time course of glutamate clearance compared to the GFP/RFP-treated
hemisphere. Local application of 250 nL of 1 mM glutamate
↑) produced
(
a robust
increase in extracellular glutamate that returned back to baseline levels through
glutamate uptake. Note that the Tc was significantly increased in the GLT-1/RFP
hemisphere. (B) Faster glutamate Tc’s in the striatal hemisphere treated with GLT-1/RFP
than the GFP/RFP-treated hemisphere. Glutamate signals were sorted by amplitude for
comparison (* p< 0.05, ** p< 0.01, n=3).
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A

B

C

Figure 4.5 Expression of green and red fluorescent protein in the striatum three
weeks after infusion of AAV-GFP and AAV-GLT-1/RFP
(A) Coronal section of the rat striatum three weeks after infusion of AAV-GFP and AAVGLT-1/RFP depicting the recording track of the MEA (scale bar = 2 mm). (B) High
magnification image of striatal hemisphere infused with AAV-GFP showing cells and
elongated process expressing green fluorescent protein (scale bar = 0.2 mm). (C) High
magnification image of striatal hemisphere infused with AAV-GLT-1/RFP showing cells
and elongated process expressing red fluorescent protein (scale bar = 0.2 m
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Figure 4.6 Similar rates of glutamate clearance in the AAV-GFP and AAV-GLT-1
treated hemispheres
Graph depicting glutamate signals with similar amplitudes (<50 µM) resulting from local
application of glutamate (↑) at three weeks post-AAV-GFP and AAV-GLT-1 infusion. The
clearance of the glutamate signal was similar between the AAV-GFP and AAV-GLT-1
treated hemispheres.
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Figure 4.7 Similar amounts of GLT-1 gene expression between the AAV-GFP and
AAV-GLT-1 treated hemispheres
Quantitative real-time PCR on striatal punches shows similar amounts of GLT-1 gene
expressions between the AAV-GFP and AAV-GLT-1 treated hemispheres (n= 6).
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Chapter Four: Tables

Table 4.1 Comparison of glutamate clearance between the AAV-GFP and AAVGLT-1 treated hemispheres
Amplitude
Range

Amplitude
(µM)

k-1
(s-1)

T80
(s)

Tc
(µM/s)

AAV-GFP (n=22)

29.4 ± 1.8

0.22 ± 0.03

5.7 ± 0.4

6.4 ± 0.8

AAV-GLT-1 (n=25)

25.1 ± 1.9

0.24 ± 0.02

5.4 ± 0.6

6.2 ± 0.6

AAV-GFP (n=17)

72.8 ± 2.7

0.28 ± 0.04

7.0 ± 1.1

14.8 ± 1.7

AAV-GLT-1 (n=12)

70.8 ± 3.0

0.30 ± 0.04

6.3 ± 0.9

15.2 ± 2.0

AAV-GFP (n=7)

153.1 ± 6.9

0.38 ± 0.06

5.3 ± 0.7

34.7 ± 4.9

AAV-GLT-1 (n=7)

126.2 ± 3.4

0.37 ± 0.06

7.3 ± 1.6

29.3 ± 3.8

(<50µM)

(50-100µM)

(>100µM)

Data shown as mean ± SEM, n= recording depth in striatum, analyzed by a two-tailed
unpaired t test.
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Preface to Chapter Five
In the previous chapters, I have demonstrated the capabilities of microelectrode
arrays (MEAs) to detect disruptions in extracellular glutamate in experimental models of
traumatic brain injury (TBI). Current, neurocritical care for severe traumatic brain injury
patients uses a multitude of neuromonitoring devices to identify secondary insults, which
are difficult to detect. We hypothesize that enzyme-based microelectrode arrays (MEAs)
can provide insight into the pathophysiological mechanisms of TBI and detect potential
biomarkers to guide the care and management of TBI patients. The purpose of this study
was to examine the translational potential and capabilities of enzyme-based
microelectrode arrays (MEAs) as a novel neuromonitoring device for clinical TBI
research.

Chapter Five: Development of a novel neuromonitor for clinical TBI
research: enzyme-based microelectrode arrays for real-time in vivo
detection of neurochemicals

Abstract
Modern neurocritical care management uses a host of monitoring techniques to
identify secondary insults and guide subsequent therapeutic interventions in an attempt
to minimize the resulting secondary brain injury in severe TBI survivors. However, the
onset and extent of secondary brain injury have been difficult to detect. We hypothesize
that enzyme-based microelectrode arrays (MEAs) can provide insight into the
pathophysiological mechanisms of TBI and detect potential biomarkers to guide the care
and management of TBI patients. The purpose of this study was to examine the
translational potential and capabilities of enzyme-based microelectrode arrays (MEAs)
as a novel neuromonitoring device for clinical TBI research. MEAs can continuously
measure extracellular glutamate during the initial 72 hours after implantation, which is
the temporal window for disruptions in extracellular glutamate previously detected in TBI
survivors. Second, selective coatings applied to the MEAs allow for simultaneous
detection of multiple neurochemicals of interest on a single device, such as
simultaneous detection of glutamate, lactate, pyruvate, and glucose. Molecules that
have been previously identified as potential biomarkers in clinical microdialysis studies.
Lastly, we were able to transfer a similar methodology of the MEAs onto an already
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FDA-approved device, the AD-TECH® Epilepsy/LTM macro-micro depth electrode, for
selective measures of extracellular glutamate both in vitro and in vivo.
Introduction
Current management strategies for traumatic brain injury (TBI) survivors are
directed towards providing an optimal physiological environment in order to minimize
secondary brain injury and maximize the body's own regenerative processes. Modern
neurocritical care management uses a host of monitoring techniques to identify
secondary insults and guide subsequent therapeutic interventions in an attempt to
minimize the resulting secondary brain injury that occurs in severe TBI survivors (Tisdall
and Smith 2007). However, the onset and extent of secondary brain injury have been
difficult to detect. A multitude of invasive neuromonitoring techniques are currently being
used in the intensive care unit to detect disruptions in intracranial pressure (ICP),
cerebral perfusion pressure (CPP), cerebral blood flow (CBF), brain tissue oxygen
tension (PbtO2), brain temperature, markers of cerebral cellular metabolism such as
glucose,

lactate,

pyruvate,

glutamate,

and

glycerol,

and

intracranial

electroencephalography (Kirkpatrick, et al. 1996, Patel, et al. 2002, Stuart, et al. 2010).
However, to date, only ICP monitoring is the standard of care for management of severe
TBI patients (The Brain Trauma Foundation, 2000). Other than ICP monitoring, no
consensus exists regarding the selection of neuromonitoring devices for specific patient
groups, the placement of devices in relation to injured brain tissue, or many of the
technical aspects of inserting the devices. At present, there is a major controversy in
whether the use of neuromonitoring devices leads to improved functional outcomes in
severe TBI patients (Stuart, et al. 2010).
The overall goals of neuromonitoring in TBI patients is to provide insight into the
pathophysiological processes of secondary brain injury, identify novel therapeutic
targets, and reliably detect a biomarker to aid in the diagnosis of TBI severity, guide
medical care, predict functional outcomes, and test the efficacy of therapeutics. While
under development, microdialysis, a method for detecting neurochemical changes in the
extracellular fluid of the central nervous system, exhibited tremendous potential as a
novel tool to uncover the pathophysiological processes of secondary brain and possibly
detect a biomarker for TBI (Hillered, et al. 1990). Microdialysis involves the implantation
of a probe, a semi-permeable membrane, that when perfused with a physiological
solution allows diffusion of small molecules into the probe to be collected and analyzed.
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Cerebral microdialysis has been used clinically for the past 20 years detecting
disruptions in the extracellular concentrations of neurochemicals involved in TBI
pathophysiology (Hillered, et al. 1990, Hillered, et al. 2005, Goodman and Robertson
2009).
Microdialysis has been widely used clinically, primarily due to its ability to detect
disruptions in the bioenergetics and metabolism of the central nervous system in severe
TBI patients that includes disruptions in lactate, pyruvate, and glucose (Persson, et al.
1996, Goodman, et al. 1999, Sarrafzadeh, et al. 2000, Vespa, et al. 2005, Wang, et al.
2007, Carpenter, et al. 2008, Marcoux, et al. 2008, Meierhans, et al. 2010, Zetterling, et
al. 2010, De Fazio, et al. 2011, Hejcl, et al. 2011, Nelson, et al. 2011, Timofeev, et al.
2011a, Yokobori, et al. 2011, Dizdarevic, et al. 2012, Oddo, et al. 2012). In addition,
microdialysis has detected increases in the excitatory neurotransmitter, glutamate,
especially in times of ischemia and energy failure (Persson and Hillered 1992, Bullock,
et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 1998, Yamamoto, et al.
1999, Reinert, et al. 2000, Sarrafzadeh, et al. 2000, Hutchinson, et al. 2002, Hlatky, et
al. 2004, Goodman and Robertson 2009, Chamoun, et al. 2010, Lakshmanan, et al.
2010, Timofeev, et al. 2011a). Although microdialysis provides insight into the
pathophysiological processes of TBI and the corresponding neurochemical changes
associated with secondary brain injury, microdialysis has failed to reliably detect a
biomarker that could be used to guide the treatment and management of severe TBI
patients. The inability of microdialysis to reliably detect a biomarker for TBI may be due
to inherent methodological limitations of the technique. First, the large sampling area of
the microdialysis probe (10 mm) and extensive damage surrounding the probe from
implantation of the device limits the ability of microdialysis to sample extracellular
neurochemicals that correspond to concentrations near the synapses (Borland, et al.
2005, Jaquins-Gerstl and

Michael 2009). Second, the temporal resolution of

microdialysis (1-20 min) is inadequate to sample the fast dynamics of neurochemical
release and clearance that occurs on the order of milliseconds that likely results in the
loss of relevant and critical information encoded in the regulation of the neurochemicals
(Diamond 2005). Lastly, collecting and analyzing the microdialysate for the
neurochemicals of interest delays examination of the data, thus limiting the usefulness of
microdialysis in guiding the management and treatment of TBI patients at the bedside.
Recently developed enzyme-based MEAs have improved upon some of the
methodological limitations of microdialysis for clinical monitoring of extracellular
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neurochemicals. The improved spatial resolution (micrometers) and limited damage to
the surrounding central nervous system during implantation of the device permits
detection of neurochemicals from synaptic sources (Day, et al. 2006, Rutherford, et al.
2007, Hascup, et al. 2008, Hinzman, et al. 2012). Since MEAs use electrochemical
methods, data can be collected on a sub-second time scale allowing the detection of
dynamic changes in neurochemicals. In addition, electrochemical detection allows data
to be collected in real-time and displayed bedside, permitting management and
treatment decisions to be based on neurochemical data. We hypothesize that enzymebased microelectrode arrays (MEAs) can provide insight into the pathophysiological
mechanisms of TBI and detect potential biomarkers to guide the care and management
of TBI patients. The purpose of this study was to examine the translational potential and
capabilities of enzyme-based MEAs as a novel neuromonitoring device for clinical TBI
research.

Materials and Methods

Animals
Male Sprague-Dawley rats were used for all experiments. The animals were
housed in a 12 h light/dark cycle with food and water ad libitum according to the
Association for Assessment and Accreditation of Laboratory Animal Care International.
Animals were acclimated to their environment for at least 1 week before any
experiments. After surgery, animals were monitored daily for post-operative care. Animal
care was approved by the University of Kentucky Institutional Animal Care and Use
Committee.

Continuous recordings of extracellular glutamate for 72 hours in awake
animals
Ceramic-based MEAs, consisting of four platinum recording sites (15 x 333 µm)
arranged in dual pairs, were prepared and selected for in vivo recordings (Burmeister, et
al. 2002, Day, et al. 2006). MEAs were prepared and coated for glutamate measures
similar to previous work with one modification (Burmeister and

Gerhardt 2001,

Burmeister, et al. 2002, Rutherford, et al. 2007, Hinzman, et al. 2010). On the sentinel
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recording sites, inactivated glutamate-oxidase was used using the same procedure and
concentrations as the active glutamate-oxidase. Glutamate-oxidase was inactivated by
autoclaving ~1.0 µL aliquot of active enzyme. Inactivated glutamate-oxidase was used to
ensure similar diffusion layers on all recording sites. The two different coatings allowed
the use of a self-referencing technique, in which the background current of the sentinel
sites can be subtracted from the current of the glutamate-oxidase sites, thereby
producing a more selective glutamate measure (Burmeister and

Gerhardt 2001,

Burmeister, et al. 2002). MEA pedestals were fabricated and constructed for chronic
glutamate measures similar to previous studies (Rutherford, et al. 2007).
Before implantation of the MEA pedestal, MEAs were calibrated to test the
capability of the MEA to measure glutamate and generate a standard curve for the
conversion of current to glutamate concentration (Hinzman, et al. 2010). Before
implanting the MEA pedestal, rats underwent a sham injury (Lifshitz 2008, Hinzman, et
al. 2010, Thomas, et al. 2011). Upon completion of the sham surgery, animals were
implanted with the MEA pedestal (Rutherford, et al. 2007). MEAs were stereotaxically
placed in the striatum (AP: +1.0, ML: + 2.5, DV: -4.0). Animals were then placed in the
recording chamber, 21 x 11 inch plexiglass rectangle, and connected to the FAST-16
mkII system via hammerhead-type pre-amplifier. Data was collected at a frequency of 4
Hz. Animals were provided with food and water ad libitum and remained on their 12 hour
light/dark cycle.
Amperometric data were analyzed using custom MATLAB® - based software.
Extracellular glutamate was calculated using the self-referencing method (Burmeister
and Gerhardt 2001, Burmeister, et al. 2002). Data were filtered using a fourier low pass
filter (0.14) and wavelet low pass filter (3). Extracellular glutamate levels were averaged
per hour.

Multiple Analyte Calibrations
MEAs were prepared and coated for the analyte of interest (Burmeister, et al.
2004) with one modification. Polyurethane was coated by hand onto selected sites
instead of dipping all sites into polyurethane. Polyurethane was only coated only on the
platinum recording sites coated with lactate-oxidase and pyruvate-oxidase. Calibrations
were conducted to test the capability of the MEA to selectively measure the analyte of
interest. The parameters tested were limit of detection (three times the standard
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deviation of the baseline noise), sensitivity to the analyte (slope), and the linear increase
in current due to additions of the analyte (R2). Constant potential amperometry was
performed with the MEAs using the FAST-16 mkII system. A potential of +0.7 V versus
an Ag/AgCl reference was applied to oxidize the reporter molecule, H2O2. The resulting
current was amplified and digitized by the FAST-16 mkII system.

Modification of FDA-approved device (AD-TECH® Epilepsy/LTM macromicro depth electrode) for in vivo detection of glutamate
AD-TECH® Epilepsy/LTM macro-micro depth electrodes were provided by ADTECH® (AD-TECH Medical Instruments, Racine, WI). Probes were prepared and coated
for glutamate measures (Hinzman, et al. 2010) with minor modifications. A 10 µL
solution of 2% bovine serum albumin (BSA), 0.25% glutaraldehyde, and 1% glutamateoxidase was prepared. Using a dissecting microscope, a microsyringe was used to
manually apply a small drop (~0.1µL) of the glutamate-oxidase solution onto the microdepth electrodes. The increased percentage of BSA and glutaraldehyde compared to
methods described in Chapters 2, 3, and 4 was used to aid in the adherence of the
coatings onto the micro-depth electrode. Multiple coats were applied to the micro-depth
electrodes until the whole electrode was encapsulated. The same procedure was used
to coat sentinel sites, micro-depth electrodes coated with a solution containing 2 % BSA
and 0.25% glutaraldehyde. After coating, the probes were cured for at least 48 hours in
a low humidity environment. The coated probes were connected to the FAST-16 mk II
system and the micro-depth electrodes were placed in a 5 mM mPD solution.
Electroplating software was used to apply a potential as a triangular wave with an offset
of -0.5V, peak to peak amplitude equal to 0.25V, at a frequency of 0.05 Hz, for a period
of 25 minutes to electroplate the mPD on the micro-depth electrodes. Probes were cured
for an additional 24 hours in a low humidity environment before use.
Calibrations were conducted to test the capability of the probe to measure
glutamate and generate a standard curve for the conversion of current to glutamate
concentration. The AD-TECH® Epilepsy/LTM macro-micro depth electrode was placed in
a continuously stirred 40 ml solution of 0.05 M phosphate buffered saline (PBS)
maintained at 37 ºC with a re-circulating water bath. The probes were exposed to final
concentrations of 250 µM AA, 20, 40, 60 µM glutamate, 2 µM DA, and 8.8 µM H2O2.
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Parameters tested were limit of detection (LOD), selectivity for glutamate over ascorbic
acid, slope of the electrode (sensitivity), and linearity of the glutamate response (R2).
Animals

were

anesthetized

with

isoflurane

and

prepared

for

in

vivo

electrochemical recordings (Burmeister, et al. 2002, Pomerleau, et al. 2003, Day, et al.
2006). Briefly, animals were placed in a stereotaxic frame and body temperature was
maintained at 37 °C with a water pad connected to a re-circulating water bath. A
craniotomy was performed to provide access to the striatum. A Ag/AgCl reference wire
was implanted into the lateral parietal cortex in the opposite hemisphere from the
recording areas. The AD-TECH® Epilepsy/LTM macro-micro depth electrode was
lowered into the brain using a microdrive. All recordings were performed at a frequency
of 4 Hz using constant potential amperometry. Glutamate was locally applied into the
striatum using a 30 gauge Hamilton needle. While the animal was under isoflurane
anesthesia, urethane was administered (1.25 g/kg i.p.).
Amperometric data were analyzed using custom MATLAB® - based software.
Extracellular glutamate was calculated using the self-referencing method (Burmeister
and Gerhardt 2001, Burmeister, et al. 2002). For local application of glutamate, data
were filtered using a fourier low pass filter (0.14). For analysis of the decrease in
extracellular glutamate from injection of urethane, data were filtered with a fourier low
pass filter (0.14) and with a 10 sec boxcar average. The data collected five minutes prior
to urethane injection and minutes 5-10 after the urethane injection were compared.

Results

MEAs can continuously measure extracellular glutamate for the inital 72
hours after implanation
Disruptions in extracellular glutamate have been detected in traumatic brain
injury survivors using microdialysis, with a vast majority of these disruptions being
detected within the first 72 hours of implantation of the microdialysis probe (Persson and
Hillered 1992, Bullock, et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al.
1998, Yamamoto, et al. 1999, Reinert, et al. 2000, Sarrafzadeh, et al. 2000, Hutchinson,
et al. 2002, Hlatky, et al. 2004, Chamoun, et al. 2010, Lakshmanan, et al. 2010,
Timofeev, et al. 2011a). To test the ability of MEAs to continuously record extracellular
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glutamate for the initial 72 hours after implantation, we implanted rats with a MEA and
recorded extracellular glutamate levels continuously in the rats for the initial 72 hours
after implantation (Fig 5.1A).
In the first animal, we recorded extracellular glutamate levels continuously for 74
hours. In the first hour, extracellular glutamate averaged 0.4 µM with a gradual rise in
extracellular glutamate over the next 10 hours reaching a maximum of 10.5 µM. Then,
extracellular glutamate levels slowly fell over the next 30 hours where the extracellular
glutamate concentration remained stable around ~1.0 µM for the remainder of the
recording (Fig 5.1B). In the second animal, we record extracellular glutamate levels
continuously for 75 hours. Similar to the first animal, there was an initial rise in
extracellular glutamate rising from 4.5 µM in the first hour to 28.2 µM thirteen hours later.
Unlike the first animal, extracellular glutamate exhibited a diurnal rhythm with sharp
increases in extracellular glutamate levels at the start of the second and third dark
cycles. The hour prior to the start of the second dark cycle, extracellular glutamate
averaged 14.4 µM sharply rising to a maximum of 22.8 µM six hours later. The hour prior
to the start of the third dark cycle, extracellular glutamate averaged 12.4 µM sharply
rising to a maximum of 17.1 µM three hours later. In the second animal, extracellular
glutamate exhibited a potential diurnal rhythm but did not reach a stable baseline during
the 75 hours of recording (Fig 5.1C). Thus, MEAs can continuously record extracellular
glutamate for at least the initial 72 hours after implantation.

Detection of multiple analytes of interest using a single MEA (glutamate,
lactate, pyruvate, or glucose)
Microdialysis studies in TBI survivors have identified certain compounds that
could be potential biomarkers for TBI, with extracellular levels of these compounds
correlating with injury severity and functional outcomes. The four molecules that have
been consistently disrupted in TBI survivors are glutamate (Persson and Hillered 1992,
Bullock, et al. 1995, Bullock, et al. 1998, Koura, et al. 1998, Vespa, et al. 1998,
Yamamoto, et al. 1999, Reinert, et al. 2000, Sarrafzadeh, et al. 2000, Hutchinson, et al.
2002, Hlatky, et al. 2004, Chamoun, et al. 2010, Lakshmanan, et al. 2010, Timofeev, et
al. 2011a), lactate and pyruvate (Persson, et al. 1996, Goodman, et al. 1999,
Sarrafzadeh, et al. 2000, Vespa, et al. 2005, Wang, et al. 2007, Carpenter, et al. 2008,
Marcoux, et al. 2008, Meierhans, et al. 2010, Zetterling, et al. 2010, De Fazio, et al.
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2011, Hejcl, et al. 2011, Nelson, et al. 2011, Timofeev, et al. 2011a, Yokobori, et al.
2011, Dizdarevic, et al. 2012, Oddo, et al. 2012), and glucose (Caspari, et al. 1992,
Persson, et al. 1996, Alessandri, et al. 2000, Vespa, et al. 2003, Meierhans, et al. 2010,
Timofeev, et al. 2011a, Timofeev, et al. 2011b, Yokobori, et al. 2011, Dizdarevic, et al.
2012).
Previous work in our laboratory has shown that MEAs can detect glutamate,
lactate, and glucose (Burmeister, et al. 2004). However, the ability of MEAs to detect
multiple analytes on a single MEA was unknown. The purpose of this experiment was to
examine the ability of a single MEA to detect multiple compounds of interest. A major
obstacle for detection of multiple compounds on a single device is the potential vast
concentration differences between the compounds. Extracellular concentrations of
glutamate and pyruvate are in the micromolar range. While extracellular concentrations
of lactate and glucose are in the millimolar range. Another obstacle for the detection of
lactate and glucose is the saturation of their corresponding oxidase enzymes. These
enzymes saturate at ~1 mM limiting the ability of the MEAs to detect physiological
concentrations. To overcome saturation of the enzymes polyurethane coatings were
developed to produce a diffusion barrier preventing saturation of the enzymes and
shifting the detectable range into the millimolar range.
The first MEA was configured for the detection of glutamate and lactate. The in
vitro calibration demonstrated the ability of the MEA to simultaneously measure
glutamate and lactate (Fig 5.2A). Additions of 20 µM glutamate produced a step-wise
increase in current on the platinum recording site coated with glutamate-oxidase with no
response on the recording sites coated with lactate-oxidase. For the glutamate-oxidase
recording site, the sensitivity to glutamate was 7.3 pA/µM (slope), detection limit of 1.0
µM (LOD), and linearity of response equal to 0.99 (R2). Additions of 2 mM lactate
produced a robust step-wise increase in current on the recording site coated with
lactate-oxidase with no response on the glutamate-oxidase site despite the large
increase in current corresponding to the high concentrations of lactate. For the lactateoxidase recording site, the sensitivity to lactate was 0.3 pA/µM (slope), detection limit of
20 µM (LOD), and linearity of response equal to 0.99 (R2). Using the polyurethane
coating, we were able to measure up to 10 mM lactate with a linear response.
The second MEA was configured for the detection of glutamate and pyruvate.
The in vitro calibration demonstrated the ability of the MEA to simultaneously measure
glutamate and pyruvate (Fig 5.2B). Additions of 20 µM and 100 µM pyruvate produced a
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corresponding step-wise increase in current on the recording site coated with pyruvateoxidase with minimal response on the glutamate-oxidase site during additions of the
pyruvate. For the pyruvate-oxidase recording site, the sensitivity to pyruvate was 1
pA/µM (slope), detection limit of 0.6 µM (LOD), and linearity of response equal to 0.98
(R2) up to 500 µM. Additions of 20 µM glutamate produced a step-wise increase in
current on the platinum recording site coated with glutamate-oxidase with no response
on the recording site coated with pyruvate-oxidase. For the glutamate-oxidase recording
site, the sensitivity to glutamate was 11 pA/µM (slope), detection limit of 0.1 µM (LOD),
and linearity of response equal to 0.99 (R2).
The third MEA was configured for the detection of glucose and lactate.
Polyurethane was coated on the recording sites coated with glucose-oxidase and
lactate-oxidase. The in vitro calibration demonstrated the ability of the MEA to
simultaneously measure glucose and lactate (Fig 5.2C). Additions of 4 mM glucose
produced a robust step-wise increase in current on the platinum recording site coated
with glucose-oxidase with no response on the recording sites coated with lactateoxidase. For the glucose-oxidase recording site, the sensitivity to glucose was 0.18
pA/µM (slope), detection limit of 12 µM (LOD), and linearity of response equal to 0.95
(R2). Additions of 4 mM lactate produced a step-wise increase in current on the
recording sites coated with lactate-oxidase with no response on the glucose-oxidase
site. For the lactate-oxidase recording site, the sensitivity to lactate was 0.022 pA/µM
(slope), detection limit of 64 µM (LOD), and linearity of response equal to 0.99 (R2).
Using the polyurethane coating, we were able to measure up to 20 mM glucose and 8
mM lactate concentrations with a reasonable linear response. Thus, with the use of
polyurethane and selective enzyme coatings, MEAs exhibit the ability to detect multiple
analytes (glutamate, pyruvate, lactate, and glucose) on a single device. MEA coatings
and calibrations were performed in collaboration with Jason Burmiester.

Modification of FDA approved device (AD-TECH® Epilepsy/LTM macromicro depth electrode) for in vivo detection of glutamate
The AD-TECH® Epilepsy/LTM macro-micro depth electrode provides up to 16
micro-electrodes (38 µM platinum wire) that could be coated similar to the MEAs for
detection of neurochemicals. The AD-TECH® Epilepsy/LTM macro-micro depth electrode
has four macro-depth electrodes with multiple rows of four micro-depth electrodes
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residing above the macro-depth electrodes (Fig 5.3A). Some of the micro-depth
electrodes were coated with glutamate-oxidase for the detection of glutamate while other
micro-depth electrodes were coated with an inactive protein matrix (sentinel sites) to
allow for self-referencing (see methods for details). Using similar coating procedures, we
were able to adhere enzyme onto the micro-depth electrodes (Fig 5.3B). The in vitro
calibration demonstrated the ability of the AD-TECH® Epilepsy/LTM macro-micro depth
electrode to selectively measure glutamate (Fig 5.3C). Addition of a major interferent
(250 µM ascorbic acid) produced little response on the glutamate-oxidase and sentinel
micro-depth electrodes. Additions of 20 µM glutamate produced a step-wise increase in
current on the micro-depth electrodes coated with glutamate-oxidase with minimal
response on the sentinel micro-depth electrode. Addition of 8.8 µM H2O2 produced an
increase in current on both the glutamate-oxidase and sentinel micro-depth electrodes.
For the micro-depth electrode coated with glutamate-oxidase, the sensitivity to glutamate
was 15 pA/µM (slope), detection limit of 0.9 µM (LOD), selectivity for glutamate over
ascorbic acid (91:1), and linearity of response equal to 0.99 (R2). Thus, we were able to
modify an AD-TECH® Epilepsy/LTM macro-micro depth electrode to selectively measure
glutamate in vitro.
Next, we examined the ability of the AD-TECH® Epilepsy/LTM macro-micro depth
electrode to measure extracellular glutamate in vivo.

The AD-TECH® Epilepsy/LTM

macro-micro depth electrode was implanted into the striatum of a rat under isoflurane
anesthesia (Fig 5.4A).

Local application of 500 µM glutamate into the rat striatum

produced a robust and rapid increase in extracellular glutamate that rapidly returned to
baseline (Fig 5.4 B). Prior to injection of glutamate, the baseline value of glutamate was
9.0µM. Local application of 500 µM glutamate produced a glutamate signal with a
maximum amplitude of 109.3 µM that decayed back to baseline levels through glutamate
uptake and diffusion from the probe. The time for the signal to decay 80 % (T80) was
11.75 s, with an uptake rate of 9.58 µM/s. In a second experiment, we examined if we
could modulate extracellular glutamate levels. Injection of urethane has been shown to
reduce extracellular glutamate levels in awake rats (Rutherford, et al. 2007). While the
rat was under isoflurane anesthesia, 1.25 mg/kg of urethane was injected i.p. Under
isoflurane anesthesia, extracellular glutamate levels averaged 1.8 µM, five minutes after
injection of urethane extracellular glutamate levels decreased by ~75% to 0.4 µM (five
minute average of extracellular glutamate) (Fig 5.5C). Thus, a modified AD-TECH®
Epilepsy/LTM macro-micro depth electrode can measure extracellular glutamate in vivo.

91

Discussion
The purpose of this study was to examine the translational potential of MEAs as
a novel neuromonitoring device for clinical TBI research. Here, we report MEAs exhibit
the properties and capabilities to be a useful tool for clinical TBI research. First, MEAs
can continuously measure extracellular glutamate for the initial 72 hours after
implantation, which is the temporal window for disruptions in extracellular glutamate in
TBI survivors. Second, MEAs can detect multiple potential biomarkers (glutamate,
lactate, pyruvate, or glucose) on a single device, molecules that have been previously
shown to correlate with injury severity and functional outcomes. Lastly, we were able to
transfer a similar methodology of the MEAs onto an already FDA-approved device, ADTECH® Epilepsy/LTM macro-micro depth electrode, for selective measures of
extracellular glutamate both in vitro and in vivo.
The use of an enzyme-based system with constant potential amperometry has
certain methodological advantages over microdialysis, currently the only in vivo method
to detect dynamic extracellular changes in neurochemicals clinically. Since constant
potential amperometry measures the current from the oxidation of H2O2 generated from
specific oxidase enzymes, data are collected at a sub-second scale with real-time data
readout at the bedside possible. Although improvements are being made for online
analysis of microdialysis samples, most studies require collection and analysis of the
microdialysate to obtain neurochemical values. Recent methodological advancements
with bedside analyzers such as the CMA ISCUSflex (CMA/Microdialysis, Sweden) permits
analysis, monitoring, and time trend display of neurochemicals that interfaces with
commonly used intensive care unit systems. However, this approach permits only
analysis of glucose, pyruvate, lactate, glycerol and glutamate (Goodman and Robertson
2009). Also, the improved spatial resolution of MEAs and limited damage to the
surrounding tissue allows sampling of neurochemicals from the synaptic pool (Day, et al.
2006, Rutherford, et al. 2007, Hascup, et al. 2008, Hinzman, et al. 2012). In contrast, the
large sampling area of the microdialysis membrane (10 mm length) and extensive
damage from implantation of the microdialysis probe, which limits the ability of
microdialysis to sample neurochemicals from the synaptic pool (Borland, et al. 2005,
Jaquins-Gerstl and

Michael 2009). Furthermore, the low temporal resolution of

microdialysis (1-20 min) is inadequate to sample the fast dynamics of neurochemical
release and clearance that occurs on the order of milliseconds to seconds (Diamond
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2005). Thus, due to these methodological improvements MEAs exhibit tremendous
potential as a clinical research tool for TBI.
Our laboratory has developed multiple MEA prototypes for clinical use. The first
prototype, Spencer-Gerhardt (SG1), embeds a S2-style MEA onto the surface of a FDAapproved device (Fig 5.5A). Embedding the MEA on the surface of an AD-TECH®
Spencer® probe provides certain advantages for clinical use. The MEAs would be able to
gain access to the central nervous system to detect extracellular neurochemicals without
the need for additional surgeries or implantations of devices. Also, embedding the MEA
on a currently used device such as the AD-TECH® Spencer® probe would reduce the
need for additional training on handling or implanting the device by neurosurgeons.
However, permanently embedding the device produces certain disadvantages such as
the inability to remove the MEA independently of the AD-TECH® Spencer® probe. Also,
placement of the MEA into the central nervous system will be limited to placement of the
AD-TECH® Spencer® probe. The second prototype, Spencer-Gerhardt (SG2), was
developed as an independent device. The SG2 has a S2-style MEA placed on the tip of
a long thin polyimide tubing (Fig 5.5B). This prototype allows the MEA to be implanted
independently and can be placed in the brain region of interest. Since the device is
independent, additional surgery and procedures will be required for implantation.
However, this will allow for independent removal of the device. Recent designs of MEAs
provide better configurations for the detection of multiple analytes. The DS-PR-8 is a
double sided MEA with 16 platinum recording sites, eight on each side arranged in pairs
(Fig 5.3C). The configuration of the DS-PR-8 could potentially allow for the simultaneous
detection of glutamate, lactate, pyruvate, and glucose on a single device. Further work is
needed to examine the capability of the DS-PR-8 to simultaneously measure all four
analytes of interest. Lastly, a third clinical prototype is in development, which combines
features of the SG1 and SG2. The third generation prototype would consist of an FDAapproved device, such as the AD-TECH® Epilepsy/LTM Behnke fried depth electrode
that has a central open lumen with an opening at the tip allowing a MEA to be inserted
through the middle of the device and extended out of the tip and into the tissue. This
strategy would reduce the need for additional surgeries and implantations while retaining
the ability to remove the device independently. Ongoing work is proceeding to evaluate
and improve clinical designs for translation of MEA technology into the clinic.
Extracellular glutamate recordings in awake animals for the initial 72 hours after
implantation revealed a substantial initial increase in extracellular glutamate in the first
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10-13 hours after implantation. The inflammatory response from implantation of
electrodes into the central nervous systems activates microglia and signals migration of
microglia to the injury site, which secrete reactive oxygen species, inflammatory
cytokines, and release extracellular glutamate (Turner, et al. 1999, Block and Hong
2005, Polikov, et al. 2005, Block, et al. 2007, McConnell, et al. 2007, Rutherford, et al.
2007). However, these responses are thought to occur over days and weeks after
implantation of the device (Turner, et al. 1999). Initial implantation of the device
damages multiple structures including capillaries, extracellular matrix, cells, and permits
blood-borne macrophage entry into the CNS (Polikov, et al. 2005). The initial damage
and subsequent cellular responses may be responsible for the initial increase in
extracellular glutamate during the initial 10-13 hours after injury. A likely source of
extracellular glutamate is from activated microglia. Also, the cytokine release from the
initial damage during implantation may produce cellular swelling and edema, shrinking
the extracellular space; thereby, increasing the extracellular glutamate concentration.
Future work, should examine if pre-treatment with an anti-inflammatory, such as
Rimadyl® (carprofen), could reduce or prevent the initial rise in extracellular glutamate.
The ability of the MEAs to simultaneously detect multiple analytes is a significant
milestone for MEA technology. Detection of only a single compound of interest was a
major disadvantage of MEAs compared to microdialysis, where multiple compounds
could be detected and analyzed. Unexpectedly, the MEAs configured for detection of
multiple analytes exhibited a similar performance for the detection of the compounds of
interest compared to MEAs configured to detect only a single analyte (Burmeister, et al.
2002, Burmeister, et al. 2004, Burmeister, et al. 2005, Hinzman, et al. 2010). Current
work on newer configurations of MEAs, such as the DS-PR-8, will allow simultaneous
detection of multiple compounds of interest. The newer designs of the MEAs with
platinum recordings sites on the front and the back of the ceramic shank will allow the
coating of oxidase enzyme on one side and the corresponding sentinel site on the other
side. The front/back design should prevent crosstalk where peroxide generated from the
oxidase enzyme diffuses to the sentinel site providing a false signal. Also, the eight pairs
of platinum recording sites arranged vertically on the ceramic shank will allow the bottom
recording sites to be “dip” coated with polyurethane, which is easier and more
reproducible than the hand coating of polyurethane onto the individual platinum
recording sites, which is necessary for the detection of lactate and glucose. Further
work is needed to optimize configurations and a coating on the newer electrode designs
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for the simultaneous detection of glutamate, lactate, pyruvate, and glucose on a single
device.
An easier path into the clinic may be modifying an already FDA-approved device
for detection of the molecules of interest. In this report, we were able to modify an ADTECH® Epilepsy/LTM macro-micro depth electrode to measure extracellular glutamate
both in vitro and in vivo. Using a similar methodology to the MEAs, we were able to coat
the microelectrode with glutamate-oxidase and an inactive protein matrix to allow for
self-referencing. The modified AD-TECH® Epilepsy/LTM macro-micro depth electrode
was able to selectively measure glutamate with similar selectivity, limit of detection, and
linearity compared to MEAs (Burmeister, et al. 2002, Hinzman, et al. 2010). However,
the sensitivity to glutamate (slope) was substantially lower on the AD-TECH®
Epilepsy/LTM macro-micro depth electrode compared to MEAs. Increasing the
sensitivity of the probe could be achieved by increasing the active surface area of the
micro-depth electrodes. One option is to increase the diameter of the platinum wire, such
as the AD-TECH® Epilepsy/LTM macro-micro depth electrode (MM14A-SP05X-000) with
50 µm platinum wires for the micro-depth electrodes. Another option is pooling multiple
micro-depth electrodes into a single channel; however, this option would increase the
background current and could reduce the spatial ability of the channel to detect
glutamate, especially if glutamate release is localized to a single micro-depth electrode.
Another way to improve the performance is to move the preamplifier closer to the
Epilepsy/LTM macro-micro depth electrode, which should reduce the noise and improve
signal detection of the probes. Future work should examine these improvements and
further evaluate the ability of FDA-approved devices for the detection of neurochemicals.
In conclusion, MEAs have tremendous potential as a clinical tool to help
understand the pathophysiology of TBI and possibly detect a reliable biomarker(s) to aid
in the diagnosis of TBI severity, guide management and care of the patient, predict
functional outcomes, and test the efficacy of therapeutics. TBI offers a unique platform
for translation of this technology into the clinic due to the large number of devices
already implanted into the central nervous system of TBI patients. Future work should
determine what enzyme/exclusion coatings would be permitted for use in the clinic,
develop a final clinical prototype, ensure performance of sterilized probes both in vitro
and in vivo, and examine damage to the central nervous system from implantation of the
device compared to other currently used devices, preferably in larger animal models.
Advancement of MEAs or MEA technology into the clinic may provide a better
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understanding of TBI pathophysiology leading to the development of novel drugs, and/or
provide an improved tool to test the efficacy of therapeutics, which could lead to
improved outcomes in TBI survivors.

Copyright © Jason Michael Hinzman 2012
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Chapter Five: Figures

Figure 5.1 MEAs can continuously measure extracellular glutamate for the inital 72
hours after implanation
(A) Rat in the recording chamber was implanted with a MEA pedestal connected to the
FAST-16 recording system via a hammerhead-type pre-amplifier. (B) Extracellular
glutamate levels in the rat striatum during the initial 72 hours after implantation,
open/closed blocks correspond to the day/night cycle. Note the initial rise in extracellular
glutamate in the first 10-13 hours that subsides over the next 24-36 hours (glutamate
averaged per hour, n=1). (C) Extracellular glutamate levels in the rat striatum during the
initial 72 hours after implantation, open/closed blocks correspond to the day/night cycle.
Note the initial rise in extracellular glutamate in the first 10 hours and subsequent
increases in extracellular glutamate that correspond with start of the night cycle on the
second and third nights (glutamate averaged per hour, n=1).
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Figure 5.2 MEAs can detect multiple analytes of interest on a single device
(glutamate, lactate, pyruvate, and glucose)
(A) Calibration of a MEA coated with glutamate-oxidase and lactate-oxidase. Four
additions of 20 µM glutamate (↑) produced a stepwise increase in current on the
recording site coated with glutamate-oxidase (red). Five additions of 2mM lactate (↑)
produced a stepwise increase in current on the recording site coated with lactateoxidase (green). Note the lack of cross talk between the glutamate-oxidase and lactateoxidase sites despite the robust signals and concentration differences between the
analytes. (B) Calibration of a MEA coated with glutamate-oxidase and pyruvate-oxidase.
Five additions of 20 µM pyrvuate (small ↑) and three additions of 100 µM pyruvate (large
↑) produced a proportional stepwise increase in current on the recording site coated with
pyruvate-oxidase (grey). Five additions of 20 µM glutamate (↑) produced a stepwise
increase in current on the recording site of the MEA coated with glutamate-oxidase (red).
(C) Calibration of a MEA coated with glucose-oxidase and lactate-oxidase. Five
additions of 4 mM glucose (↑) produced an increase in current on the recording site of
the MEA coated with glucose-oxidase (blue). Two additions of 4mM lactate (↑) produced
an increase in current on the recording site coated with lactate-oxidase (green). Results
obtained in collaboration with Jason Burmeister.
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Figure 5.3 Modification of FDA-approved device AD-TECH® Epilepsy/LTM macromicro depth electrode for real-time glutamate measures using constant
potential amperometry
(A) Picture of AD-TECH® Epilepsy/LTM macro-micro depth electrode. (B) Inset,
depicting a micro-electrode in between two macro-electrodes that has been coated
with glutamate-oxidase for detection of glutamate. (C) In vitro calibration measuring
the change in current on the micro-electrode coated with glutamate-oxidase (red)
and micro-electrode coated with inactive protein matrix (sentinel, black). Addition of
an interferent (↑) ascorbic acid produced no change in current on the glutamateoxidase or sentinel sites. Three glutamate additions (↑) showed a stepwise increase
of current on the glutamate-oxidase site with no response on the sentinel site.
Addition of H2O2 (↑) produced an increase in current on both the glutamate-oxidase
and sentinel site.
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Figure 5.4 In vivo detection of extracellular glutamate using modified AD-TECH®
Epilepsy/LTM macro-micro depth electrode
(A) Picture showing the AD-TECH® Epilepsy/LTM macro-micro depth electrode
implanted in the striatum of an anesthetized rat. (B) Local application of 500 µM
glutamate (↑) into the rat striatum produced a robust and rapid increase in extracellular
glutamate that rapidly returned to baseline. Inset, depicts the change in current from
local application of 500 µM glutamate on a micro-electrode coated with glutamateoxidase and a micro-electrode coated with an inactive protein matrix (sentinel). Note the
lack of response on the sentinel channel. (C) Extracellular glutamate levels decreased
after an injection of urethane. While the animal was under isoflurane anesthesia 1.25
mg/kg of urethane was injected i.p. Under isoflurane anesthesia extracellular glutamate
levels averaged 1.8 µM, five minutes after injection of urethane extracellular glutamate
levels decreased by ~75% to 0.4 µM (five minute average of extracellular glutamate).

101

102

Figure 5.5 MEA prototypes for clinical use
(A,) Picture of Spencer-Gerhardt (SG1) electrode, a modified AD-TECH® Spencer®
probe with a S2-style MEA embedded on the surface of the probe. Higher magnification
images show the S2-style MEA embedded on the surface of the AD-TECH® Spencer®
probe. (D) Picture of second generation of the Spencer-Gerhardt (SG2) electrode with a
S2-style MEA placed on the tip of a polyimide tubing to allow for implantation into deeper
brain structures. (E) Double-sided MEA (DS-PR-8) with 16 platinum recording sites,
eight on each side, to allow for the detection of multiple analytes of interest on a single
device. Images courtesy Peter Huettl.
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Chapter Six: Overall Conclusions
In summary, we have detected several disruptions in the regulation of
extracellular glutamate in the rat striatum two days after a diffuse brain injury. First, we
detected significant increases in tonic glutamate with tonic glutamate levels correlating
with the severity of injury. Second, we determined the contribution of pre-synaptic
calcium channel-dependent neuronal glutamate release to extracellular glutamate was
significantly decreased in brain-injured animals compared to uninjured animals. Third,
the amplitude of glutamate released from local stimulation with KCl was significantly
greater in the striatum of brain-injured animals compared to uninjured animals. Fourth,
brain-injured animals exhibited slower clearance of extracellular glutamate compared to
uninjured animals, due primarily to decreases in glutamate uptake. These results are
depicted in schematic format to highlight the disruptions in the regulation of extracellular
glutamate in the rat striatum two days after diffuse brain injury (Fig 6.1).
Although tonic glutamate levels were significantly increased in the dentate gyrus
and striatum two days after diffuse brain injury, the extracellular concentrations of
glutamate do not appear to reach excitotoxic levels as a continuous infusion of 1.8 M
glutamate at 0.5 µL/hr was insufficient to produce a neuropathological lesion (Mangano
and Schwarcz 1983). However, the post-traumatic increases in tonic glutamate may
play a role in a slower, indirect form of excitotoxicity that is mediated by physiological
concentrations of glutamate and is thought to be involved in chronic neurodegenerative
disorders such as Parkinson's disease, Huntington's disease, amyotrophic lateral
sclerosis, and Alzheimer's disease (Albin and Greenamyre 1992, Beal 1992b). “Slow
excitotoxicity” involves mitochondrial damage producing an overall reduction in
intracellular ATP that impairs the ability of the Na+/K+ ATPase to maintain the resting
membrane potential (Greene and Greenamyre 1996, Doble 1999). The loss of a stable
membrane potential leads to cellular depolarization, removal of the magnesium block
from the NMDA receptor, and opening of voltage-gated calcium channels. With cellular
depolarization and removal of the magnesium block, the NMDA receptor is more
susceptible to activation by ambient or even slightly elevated levels of extracellular
glutamate (Beal 1992a, Greene and Greenamyre 1996, Doble 1999). Over prolonged
periods of time, slight increases in the activation of the NMDA receptors can activate the
same pathophysiological processes of acute excitotoxicity responsible for neuronal
death (Olney and

de Gubareff 1978, Doble 1999). Slow excitotoxicity may be the
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pathophysiological mechanism responsible for the increased risk of epilepsy,
Parkinson’s disease, and

Alzheimer's disease in TBI survivors (Masel and

DeWitt

2010). Persistent changes in glutamate regulation in the thalamus and somatosensory
cortex have been detected up to 28 days post-injury, suggesting long-term disruptions in
glutamate regulation (Thomas, et al. 2011). Further work is needed to determine if
disruptions in the regulation of extracellular glutamate will hold true for later time points
or indefinitely, providing further evidence for “slow excitotoxicity” as a chronic
pathophysiological mechanism of TBI.
Damage from the mechanical forces of the primary brain injury and resulting
secondary injury leads to neuronal death and disruption of functional neuronal circuits.
The plasticity of the central nervous system facilitates re-connections of synapses and
reformation of neuronal networks (Wieloch and Nikolich 2006). This plasticity can be
adaptive, re-establishing functional connections or bypassing the damaged area,
resulting in normal neurological function; or the plasticity can be maladaptive, forming
dysfunctional connections and circuits responsible for producing neurological deficits.
Post-traumatic increases in extracellular glutamate may aide maladaptive plasticity
forming dysfunctional neuronal connections. Pro-inflammatory cytokines, which are
released after TBI, alter the composition, trafficking, and distribution of glutamate
receptors leading to increased expression of receptors on the cell surface (Beattie, et al.
2010). The increased surface expression of glutamate receptors in combination with
increased extracellular glutamate levels may lead to activation of receptors under
ambient conditions. Also, post-traumatic increases in extracellular glutamate could lead
to the activation of glutamate receptors extrasynaptically or on neighboring synapses,
disrupting neuronal signalling. Activation of extrasynaptic NMDA receptors alters the
trafficking, surface expression, and function of NMDA receptors, which can result in
eliptogenesis (Luhmann, et al. 1995, Frasca, et al. 2011). Further work is needed to
determine if improved glutamate regulation after a TBI prevents or reduces the
neurological deficits associated with maladaptive plasticity, such as post-traumatic
epilepsy or sensory sensitivity observed in animal models (D'Ambrosio, et al. 2004,
McNamara, et al. 2010, Thomas, et al. 2011).
Tonic glutamate levels in the striatum of brain-injured rats were insensitive to the
calcium channel blocker ω-conotoxin compared to uninjured animals, suggesting a
limited contribution of calcium-dependent vesicular glutamate release to tonic glutamate.
This could be explained by either a post-traumatic decrease in neuronal glutamate
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release with a concurrent increase in non-neuronal sources of glutamate, or a posttraumatic alteration in the mechanism of vesicular glutamate release that is independent
of calcium entry through the calcium channel. Regardless of the mechanism, our data
would suggest sodium or calcium channel blockers, may be ineffective in reducing
extracellular levels of glutamate. Although we did not detect a significant decrease in
extracellular glutamate from transient activation of mGluR2/3, future studies should
examine if long-term activation of the glutamate autoreceptors mGluR2/3, which inhibit
presynaptic glutamate release and increase expression of the glutamate transporters,
can improve the regulation of extracellular glutamate (Nakanishi 1994, Di Iorio, et al.
1996, Battaglia, et al. 1997, Allen, et al. 1999, Schoepp 2001, Zhou, et al. 2006).
Glutamate clearance was significantly slower in the striatum of brain-injured rats
compared to uninjured rats, with the decrease in glutamate clearance primarily due to
decreases in glutamate uptake. Post-traumatic decreases in glutamate uptake are likely
responsible for the increases in tonic glutamate levels and evoked glutamate release
detected in the striatum of brain-injured rats. Decreased expression of the glutamate
transporters (EAATs) has been detected both clinically and in experimental models of
TBI, suggesting post-traumatic reductions in glutamate uptake plays a pivotal role in the
pathophysiology of secondary brain injury (Rao, et al. 1998, van Landeghem, et al.
2001, Yi, et al. 2005, van Landeghem, et al. 2006, Yi and Hazell 2006). Reduced
glutamate uptake may lead to increased activation of glutamate receptors and fail to
contain glutamate release within a single synapse permitting glutamate spillover to
neighboring synapses. Further work is needed to pinpoint the mechanism responsible
for decreased glutamate uptake in brain-injured rats; biotinylation of the EAATs could
examine the surface expression of the receptors and possible oxidative damage to the
receptors to determine if reduced glutamate uptake is due to lower expression of the
EAATs and/or a decrease in the function of the EAATs (Trotti, et al. 1998, Nickell, et al.
2007).
Since we detected decreases in glutamate uptake in the striatum of brain-injured
rats, we wanted to examine therapeutic strategies to increase glutamate uptake and
improve glutamate regulation. At the time, intraperitoneal administration of a beta-lactam
antibiotic (ceftriaxone) was the only known method to increase the expression of
glutamate transporters in the rat brain (Rothstein, et al. 2005). Furthermore,
administration of ceftriaxone was shown to reduce neuronal damage and improve
behavioral outcomes in a rat model of stroke, providing evidence that increasing
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glutamate transporters is a viable approach to prevent/reduce excitotoxicity (Chu, et al.
2006, Chu, et al. 2007). However, this approach was unable to target the expression of
the glutamate transporters into the brain region of interest, which may disrupt glutamate
signaling in undesired regions producing similar adverse effects seen with glutamate
receptor antagonist (Blanke and VanDongen 2009). The overall goal of our viral studies
was to identify a novel therapeutic approach that could target the expression of
glutamate transporters into the brain region of interest to prevent/limit excitotoxicity while
limiting adverse effects. Using a viral-vector mediated gene delivery approach (AAVGLT-1) we were able to increase the expression of functional GLT-1 into the rat striatum.
Work by our collaborator (Dr. Brandon Harvey) showed that intracerebral infusions of
AAV-GLT-1 into three cortical sites in the distribution of the right middle cerebral artery
prior to occlusion, reduced cerebral infarction, improved functional recovery, reduced
ischemia-induced glutamate overflow, and reduced tissue damage (Harvey, et al. 2011).
This work further validates the theory that increasing expression of glutamate
transporters can improve glutamate regulation, reduce excitotoxicity, and improve
outcomes in a model of excitotoxicity. With further development, viral-vector mediated
gene delivery of glutamate transporters may be a viable therapeutic strategy to treat
neurological disorders involving chronic dysregulation of glutamate. However, the
amount of time needed for stable expression of the glutamate transporters (~ 3 weeks)
limits the ability of this technique to treat acute excitotoxicty seen in stroke and TBI.
Recently, novel activators of GLT-1 have been identified that produce a rapid increase in
the expression of the transporter within 24 hours (Xing, et al. 2011). Further work should
examine the potential of these compounds to prevent/limit acute excitotoxicty in stroke
and TBI animal models.
Presently, there are no approved therapeutics for the treatment of TBI, instead
current medical care focuses on maintaining proper physiological parameters such as
blood pressure and intracranial pressure (ICP) (Wang, et al. 2006). A major problem
hindering the development of successful therapies into the clinic is an inability to model
the severity and complexity of severe TBI, which may explain why therapies developed
and tested in animal models of TBI have failed to show a clinical benefit (Bullock, et al.
1999). To gain better insight into the physiology of a severe TBI, a multitude of invasive
neuromonitors have been developed in the past 20 years. These neuromonitors are
currently being used to detect the pathophysiological mechanisms of severe TBI and find
a reliable biomarker that could aid in the diagnosis of TBI severity, guide patient care
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and management, predict functional outcomes, and test the efficacy of therapeutics
(Kirkpatrick, et al. 1996, Patel, et al. 2002, Stuart, et al. 2010). However, only ICP
monitoring is currently in the standard of care for management of severe TBI patients
(The Brain Trauma Foundation, 2000); emphasizing the need for improved tools to
detect the pathophysiological mechanisms of TBI.
We hypothesize that enzyme-based microelectrode arrays (MEAs) can provide
insight into the pathophysiological mechanisms of TBI and detect potential biomarkers to
guide the care of TBI patients. In chapter Five, we demonstrated the potential of MEAs
as a novel neuromonitoring device for severe TBI to help understand the
pathophysiology of TBI and possibly detect a reliable biomarker(s). TBI offers a unique
platform for translation of MEA technology into the clinic for a variety of reasons. First,
there is a large amount of evidence from clinical microdialysis studies confirming
glutamate,

lactate,

pyruvate,

and

glucose

as

potential

biomarkers

for

TBI,

neurochemicals that MEAs can reliably detect. Second, MEA technology exhibits certain
methodological advantages compared to microdialysis for in vivo detection of
neurochemicals in a clinical setting, such as improved spatial and temporal resolution,
limited damage to the central nervous system, and real-time data readouts at the
bedside. Third, a multitude of invasive neuromonitors are already being used in severe
TBI patients, providing a clear path into the clinic with the rationale, protocols, and
procedures already in place for implantation and recording from these devices. Overall,
there is a substantial amount of evidence that the care and management of severe TBI
patients may benefit from translation of MEA technology into the clinic.
A tremendous amount of work is still needed to make the translational leap into
the clinic. We need to design a final clinical prototype with consultation from
neurosurgeons to ensure practical functionally of the device. Once the devices are
manufactured, we need to ensure that the probes will remain functional after sterilization.
Previous work in our lab by Dr. Michelle Stephens has already identified a viable
sterilization procedure that should be successful (Stephens, et al. 2010). In addition, we
need to determine if we can improve the reliability of the enzyme coatings allowing the
performance of the MEAs to be predicted from the initial H2O2 calibration. Using the
H2O2 calibration prior to enzyme coatings, instead of the traditional glutamate calibration
that is used prior to implantation in animals, would negate the need for pre-calibrations
prior to implantation into the central nervous system, which may not be possible in the
clinical situation. With advice from neurosurgeons and researchers, we need to develop
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implantation procedures and protocols with a major focus on determining the placement
of the probe (white/grey matter, normal/peri-lesional tissue) in the various types of brain
injuries (diffuse, focal, subarachnoid hemorrhage, etc.). Furthermore, parameters or
tests need to be developed to ensure proper functioning of the device. Lastly, the
software for readout and analysis of the data needs to be compatible with currently used
ICU equipment and software. Overall, advancement of MEA technology into the clinic
may provide insights into the pathophysiology of TBI leading to the development of novel
drugs, and/or provide a tool that can reliably detect a biomarker to aide in the diagnosis
of TBI severity, guide patient care and management, predict functional outcomes, and
test the efficacy of therapeutics, which may lead to improvements in the outcomes of TBI
survivors.
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Chapter Six: Figures

Figure 6.1 Schematic depicting the disruptions in the regulation of extracellular
glutamate in the rat striatum two days after diffuse brain injury
In brain-injured rats, we detected post-traumatic disruptions in the regulation of
extracellular glutamate that include (1) increased tonic glutamate levels, (2) reduced
contribution of calcium-dependent glutamate release to tonic glutamate, (3) increased
amplitudes of evoked glutamate release, (4) slower glutamate clearance primarily due to
decreases in glutamate.
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